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      Abstract 
 
 
Physicochemical modulation of huntingtin aggregation on lipid membranes: Implications 
for Huntington's disease 
 
 
      Maxmore Chaibva 
 
 
 Huntington disease is a genetic, neurodegenerative disease caused by an expanded 
polyglutamine (polyQ) in the first exon of the huntingtin (htt) protein, facilitating its aggregation, 
leading to the formation of a diverse population of potentially toxic aggregate species, such as 
oligomers, fibrils, and annular aggregates. Htt interacts with a variety of membranous structures 
within the cell, and the first seventeen amino acids (Nt
17
) of htt directly flanking the polyQ 
domain is an amphipathic α-helix (AH) lipid-binding domain. AHs are also known to detect 
membrane curvature. Nt
17
also promotes diverse aggregate species of htt and undergoes a number 
of posttranslational modifications that can modulate htt’s toxicity, subcellular localization, and 
trafficking of vesicles. To get in-depth mechanistic insights of huntingtin aggregation, both 
chemical and physical modulators of the aggregation process were explored. Specifically, the 
importance of htt acetylation and the role of membrane curvature on htt aggregation were 
investigated using atomic force microscopy (AFM), which has become a robust technique to 
obtain physical insights into the formation of toxic protein aggregates associated with amyloid 
diseases on lipid membranes. Acetylation of htt exon 1, and synthetic truncated htt exon1 
mimicking peptide (Nt
17
Q35P10KK) was achieved using a selective covalent label sulfo-N-
hydroxysuccinimide (NHSA) in molar ratios of 1x, 2x, and 3x NHSA per peptide. Htt 
acetylation was found to decrease fibril formation in solution and promoted the formation of 
larger globular aggregates. Acetylation strongly altered htt’s ability to bind lipid membranes. 
 
 
However, one of the several limitations associated with using these current flat, supported 
bilayers as model surfaces is the absence of membrane curvature, which can heavily influence 
the interaction of proteins at lipid interfaces. Using an AFM force reconstruction technique, 
silicon substrate, and silica nanobeads, model lipid bilayer system was developed and validated 
in which the underlying solid support is comprised of flat and curved regions to induce regions 
of curvature in the bilayer. This model bilayer system was exposed to Nt
17
Q35P10KK peptide, and 
this peptide preferentially bound and accumulated to curved membranes, consistent with the 
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1.  Protein aggregation and Huntington’s disease 1 
 
 
1.1 Neurodegenerative diseases 
 The molecular pathway associated with a vast number of neurodegenerative 
diseases, including Huntington’s disease (HD), Alzheimer’s disease (AD) and 
Parkinson’s disease (PD), is characterized by protein misfolding, resulting in the 
aggregation of the misfolded protein, and its deposition,  and accumulation in cellular 
compartments as nanoscale aggregates [1, 2]. Proteins are synthesized as linear chains of 
several amino acids, and most properties adopt a well-defined three dimensional compact 
structure during folding for them to be functional. The main driving force for protein 
folding is the tendency for hydrophobic residues within the protein surface to interact 
together rather than with water, a phenomenon known as the hydrophobic effect. This 
leads to the burial of nonpolar side chains in the interior of proteins, leading to the 
“collapse” of the protein from an extended coil to a more defined, globular structure. 
Proteins are at risk of misfolding in which a protein is trapped in a local energy minimum 
and become misfolded. These misfolded proteins can follow a complex pathway that 
leads to the formation of fibrils rich in β-sheet structures via intermediate species such as 
oligomers (Fig. 1), and these aggregates will eventually accumulate as inclusions in the 
brain of diseased victims. The deposition of these inclusion bodies is the hallmark of 
many neurodegenerative diseases.  It remains controversial whether the small, potentially 
diffusible assemblies, or mature amyloid fibrils, are primary culprits in neuronal 
dysfunction and death [3-5]. 
                                                          
1 This chapter includes the review that was co-authored with James Arndt with equal contribution: The 
Emerging Role of the First 17 Amino Acids of Huntingtin in Huntington’s disease. 
1. Introduction 
  2 
 
  
In this introductory chapter, the Huntington’s disease protein will be discussed, including 
the role of the protein’s first seventeen amino acids on modulating its aggregation, 
kinetically and morphologically on lipid membranes. 
 
1.2 Huntington’s disease (HD) 
 HD is a fatal, progressive neurodegenerative disorder with well-established 
origins and affects specific neurons in the brain.  This monogenic disorder is caused by a 
single mutation in the IT15 gene that code for Huntington protein, huntingtin (htt). The 
 
Figure 1. A schematic model for htt aggregation. A native monomer can sample a 
variety of distinct, misfolded monomer conformations. There appears to be to generic 
aggregation pathways toward the formation of fibrils structures. One of these pathways 
proceeds through oligomeric intermediates (A), some of which may be facilitated by 
Nt
17
. Oligomerization can also lead to the formation of large amorphous aggregates. All 
of these higher order aggregates may accumulate together to form the large inclusions 
that are a hallmark of HD. 
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mutation occurs as a CAG trinucleotide expansion in the gene. CAG codes for the amino 
acid glutamine, and therefore, the mutation leads to an expansion of a polyglutamine 
(polyQ) tract near the N-terminus of the protein htt [6]. This polyQ expansion directly 
leads to htt aggregation into fibrils and a variety of other aggregates [7-9], as shown in 
Fig. 1. While the exact mass of htt is dependent on the size of the polyQ domain, full-
length htt consists of 3144 amino acids (figure full length), 67 exons, and is 
approximately 350 kDa in weight [6]. The polyQ domain begins at the 18
th
 residue of htt 
and is contained in exon 1. For the studies presented here, the htt fragment (htt exon1) not 
the full protein was used .Several lines of evidence suggested that N-terminal fragments 
comparable to exon 1 are directly involved in HD [10-15]. For instance, expression of htt 
exon1 with an expanded polyQ tract causes a progressive neurological phenotype 
(including incoordination, gait instability, cognitive abnormality, weight loss, progressing 
to early death) in R6/2 transgenic mice [13, 16]. More recent studies demonstrated that,  
N-terminal fragments comparable to exon1 are detected in knock-in mouse models 
expressing full length htt [14], and fragments of the size of exon1 have been detected in 
HD patients [17]. Finally, it has not been possible to recombinantly express and purify 
the full htt protein. The polyQ domain is flanked by the first 17 amino acids at the N-
terminus (Nt
17
) of the protein and by a polyproline (polyP) stretch on its C-terminal side 
(Fig.2a). One of the key aspects of HD is that there is a threshold length of the polyQ 
domain required for disease with a tight correlation between both the age of onset and 
severity of disease with the increasing length of the polyQ expansion. Specifically, 
individuals with CAG repeat lengths less than 35 in their DNA sequence will not get the  
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disease, 35–39 repeats may elicit disease, 40–60 repeats cause adult onset, and juvenile 
forms of HD are associated with repeats greater than 60 [18-20]. Symptoms typically 
begin between 35-50 years, followed by 15-20 years of progression before death [21]. 
 
1.3 Protein aggregates in HD 
 The role of aggregates in HD is a complex issue and remains to be clearly 
understood. Biochemically and biophysically, it has been demonstrated that htt fragments 
containing expanded polyQ tracts readily form detergent-insoluble protein aggregates 
with characteristics of amyloid fibrils [22, 23]. Furthermore, the rate of aggregation into 
Figure 2. Schematic of important features of of htt exon1, with (a), showing Nt
17
 
(purple), polyQ (red) and the polyP (blue) regions. b) View down the barrel of the α-
helix showing relative hydrophobicity of each residue as well as the sites of reported 
posttranslational modifications. The colors on (a) don’t correspond to (b) 
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fibrils is highly correlated with polyQ length in synthetic peptides and htt exon1 
fragments [24]. This correlation between aggregation rate and polyQ length has been 
recapitulated in cell culture models expressing htt fragments [25-27]. While it is clear that 
htt with expanded polyQ tracts assemble into fibrils, htt also forms spherical and annular 
oligomeric structures [9, 28, 29]. It is therefore evident that htt can form a variety of 
aggregate structures; however, the precise mechanisms by which these structures induce 
toxicity and neurodegeneration is unclear. Precise characterization of the possible 
aggregation pathways and the resulting heterogeneous mixtures of aggregates, as well as 
factors that modulate protein aggregation is a vital step in understanding htt aggregation. 
 Extensive research has been performed to determine the kinetics of htt 
aggregation and to determine specific aggregate species on and off pathway to fibril 
formation [24]. In this regard, several aggregation pathways have been proposed for the 
formation of fibrils of polyQ-containing proteins. Two of the more prominent 
aggregation schemes are: 1) re-arrangement of a monomer to a thermodynamically 
unfavorable conformation that directly nucleates fibril formation and 2) the formation of 
soluble oligomeric intermediates that slowly undergo structural re-arrangement into a β-
sheet rich structure leading to fibrils (Fig. 1). The precise nature of the oligomeric 
aggregates associated with the second scheme can be quite heterogeneous [30, 31], and 
there could be a variety of oligomeric species that are off-pathway to fibril formation. 
While polyQ peptide fibrils share many classical features associated with amyloids, 
initial reports using pure polyQ peptides supported the nucleation-elongation model for 
the formation of polyQ fibrils [32, 33]. Subsequent studies have suggested other potential 
mechanisms associated with the potential of smaller aggregates of polyQ proteins 
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appearing prior to nucleation of fibril formation [34, 35]. Small oligomers, displaying 
various degrees of stability, of polyQ peptides with various glutamine lengths were 
observed by atomic force microscopy (AFM) [7]. Studies of polyQ peptides that were 
interrupted by other amino acids further support the formation of oligomers [36]. While 
many oligomers were observed to directly initiate fibril formation when individually 
tracked in solution, many fibrils appeared to form without any obvious oligomeric 
precursors [7]. Such observations suggest that these aggregation pathways are not 
mutually exclusive, making the situation considerably more complicated. AFM studies of 
a variety of htt-exon 1 fragments have shown that aggregation reactions result in 
heterogeneous mixtures of distinct aggregate morphologies in a polyQ length- and 
concentration-dependent manner [7]. Novel oligomers of htt exon1 have also been 
identified in an in vitro mammalian system [30]. Due to the complexity of htt 
aggregation, there is no clear consensus on the aggregate form(s) that underlie toxicity, 
and there likely exist bioactive oligomeric aggregates undetectable by traditional 
biochemical and electron microscopic approaches that precede symptoms. While 
identification of the toxic specie(s) of htt that trigger neurodegeneration in HD remains 
elusive, such species might exist in a diffuse, mobile fraction rather than in inclusion 
bodies [37].   
 Mutant htt is detected in patients’ brains predominantly as microscopic inclusion 
bodies in the cytoplasm and nucleus [13]; however, htt is also associated with a variety of 
membranous organelles, including mitochondria, endoplasmic reticulum, tubulovesicles, 
endosomes, lysosomes and synaptic vesicles [16, 38-41]. The precise mechanisms by 
which htt aggregates are toxic to neural cells, leading to the extensive cellular destruction 
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that is the hallmark of HD, remain unclear. As a result, there is a pressing need to 
understand factors that modulate htt aggregation, contribute to pathogenesis, and could 
potentially serve as therapeutic targets. The Nt
17
 could be very important in modulating 
htt aggregation. 
 
1.4 The first seventeen amino acids of huntingtin (Nt
17
) 
 A potential mechanism by which Nt
17
 influences toxic htt aggregation is that the 
formation of abnormal aggregates of mutant htt is directly influenced by this domain. 
Indeed, Nt
17
 has been implicated in driving the initial phases of htt exon 1 interaction [39, 
42-45]. Several mechanisms have been proposed that are mediated by Nt
17
. Most agree 
that the initial phase of aggregation when Nt
17
 is present begins with self-association of 
this domain, resulting in the formation of small, α-helix rich oligomers [46-48]. As such, 
it appears that Nt
17
 promotes fibril formation via the oligomer mediated pathway. In a 
cellular environment, pathogenic htt exon 1 oligomer populations do not appreciably 
change even with recruitment of monomers into inclusion bodies, suggesting that the 
formation of oligomeric species mediated by Nt
17
 is the rate-determining step [49, 50]. 
Since oligomers are widely considered to be the toxic species in Huntington’s disease, the 
promotion of oligomerization by Nt
17
 could have potentially important consequences of 
htt-related toxicity. PolyQ peptides that do not have the N-terminal flanking sequence 
tend not to form oligomeric intermediates and as a result, proceed directly to fibrillar 
aggregates [51, 52]; although, some pure polyQ-peptide oligomers have been observed to 
form when aggregating on a surface [7, 53]. The addition of a myc-tag preceding Nt
17
 in 
full htt exon 1 reduces the formation of oligomers in vitro without changing the rate of 
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fibril formation when compared to exon 1 proteins of similar polyQ length that lacked 
this myc-tag [54], suggesting that the ability of Nt
17
 to promote oligomerization can be 
interfered with by steric hindrances. Such findings seem to suggest that Nt
17
 could a good 
target for therapeutic intervention. 
 





 domain can form an amphipathic α-helix (AH) that is conserved in at 
least some aggregate forms of htt [44, 52, 55]. There are several important biophysical 
properties associated with AHs [56], but in particular, AHs are often associated with 
binding of lipid membranes [57, 58]. Briefly, an AH consists of a predominately 
hydrophilic face and a predominately hydrophobic face (Fig. 2b). AHs have been shown 
to have several functional properties such as preferentially sensing and binding highly 
curved membrane by detecting defects induced by curvature [59]. Due to their ability to 
weakly bind membranes, their interaction with membranes is easily regulated. Nt
17
 has 
been shown to sequester truncated htt exon1 peptides to regions of curvature on 
supported lipid bilayers [60]. The structure of an AH is compatible with the formation of 
a variety of helix bundles in aqueous environment that is driven by maximizing the 
interaction of the hydrophobic faces of adjacent helices [61, 62]. Due to this, the 
association of Nt
17
 via the formation of interacting AHs has been proposed to play a role 
in the initial stages of htt aggregation. The Nt
17
 primary sequence contains three 
positively charged lysine residues at positions 6, 9, and 15. Residues 6 and 15 lie at the 
boundary between the hydrophilic and hydrophobic faces in a theoretical AH that extends 
the entire length of Nt
17
 (Fig. 2b). Additionally, two methionine, two serine, and two 
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glutamic acid residues also reside on the hydrophilic face. The hydrophobic face consists 
of two phenylalanine residues, three leucine residues, and an alanine residue, with a 
leucine and a phenylalanine at each side of the boundary. It would appear that residues in 
the boundary region are critical in lipid membrane binding and intermolecular interaction. 
Simulation of lipid membrane association show K6 and K15 are strong hydrogen bond 
donors with lipid bilayers [63]. Similarly, K6 was found to be protected from an 
aggregated state by solution phase deuterium exchange mass spectrometry [64]. These 
studies point to critical interactions involving amphipathic helices that can potentially be 
involved in the formation of the previously mentioned oligomeric precursors to fibril 
formation that are mediated by Nt
17. Compelling evidence demonstrates that the α-helix 
is conserved in fibrils [44, 64, 65]. Additionally, ssNMR chemical shifts indicate residues 
4 – 11 are in an α-helical arrangement within a fibril structure, while residues 17 – 19 
have a clear β-sheet structure [44]. While there is little doubt that Nt17 is capable of 
forming an AH, under what conditions Nt
17
 adopts this structure in monomeric htt and 
the related consequences for aggregation are of critical importance. 
1.4.2 Nt
17
 as a potential therapeutic target on htt exon 1 
 From the ongoing discussion, it is clear that Nt
17
 has been implicated in the 
formation of the toxic intermediates, it represents a novel target to inhibit (or alter) 
aggregate formation, thereby possibly alleviating htt-mediated toxicity. A more practical 
means of inhibiting N-terminal aggregation is through structural complexation, either by 
small molecules, molecular chaperones or an antibody-antigen that interacts directly with 
this domain [66-71]. Interestingly, free Nt
17
 (lacking any polyQ) has been used to inhibit 
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-mediated formation of Nt
17
Q37P10K2 peptides in vitro [51, 52]. The mechanism by 
which Nt
17
 inhibits amyloid formation appears to be identical to the mechanism by which 
nucleation occurs, with the caveat that Nt
17
 alone does not contain an amyloidogenic 
polyQ tract. This increases the distance between adjacent polyQ tracts and the energy for 
polyQ fibrillization to occur [52]. It has also been known for some time that molecular 
chaperones can modulate htt aggregation [72, 73]. Many of these molecular chaperones, 
including Hsc79 [74] and Tric [68, 69], have been shown to bind directly to Nt
17
. 
Specifically ,it was found out that an intrinsically disordered chaperone, HYPK interacts 
with Nt
17
 in htt and modulates aggregate formation and cytotoxicity in neuronal cell lines 
[75]. 
 Another potential therapeutic strategy that has been extensively studied is the use 
of antibodies; unlike peptide therapeutics and inhibitors, antibodies are specific only for 
the target antigen. Several antibodies exist for htt exon 1, each recognizing distinct 
domains and potentially distinct monomers or aggregates [31, 76-79]. In the past decade, 
intracellular antibodies, or intrabodies, for Nt
17
 have been developed that inhibit htt exon 
1 fibrillization and cytotoxicity in vitro and cellular huntingtin model, two of which are 
scFv and VL 12.3.[66, 67, 80]. When co-transfected with htt exon 1 (104Q) into COS-7, 
BHK-21, and HEK-293 cells, C4 scFv was shown to decrease aggregate formation 
relative to control groups that were not transfected with the intrabody [80]. C4 scFv 
bound to htt exon 1 structures of non-pathogenic length (25Q), as well, which indicates 
the polyQ conformation does not play a role in intrabody binding, and that the most likely 
binding target is Nt
17
 [80]. These studies show that structural inhibition of Nt
17
 is 
certainly a viable means of inhibiting aggregation and, potentially, htt exon 1 toxicity.  
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 also contains numerous sites that can be post-translationally modified, with 
some sites associated with multiple potential modifications (Fig. 2b) [81-83]. These 
PTMs appear to have a profound effect on htt function and translocation [84-86], as well 
as toxicity associated with htt containing expanded polyQ domains [81, 82, 87-89]. Most 
prevalent forms of PTMs occurring in Nt
17
 are phosphorylation [43, 89-92], acetylation 
[93], ubiquitination [94] , and SUMOylation [81, 87]. Other htt modifications such as 
palmitoylation [95] and transglutamination [96] have also been observed.  
 The htt Nt
17
 domain has three potential phosphorylatable sites: threonine 3, 
(Thr3), serine 13 (Ser13), and serine (Ser16) (full length htt can also be phosphorylated at 
serine residues downstream from the N terminal domain. Numerous studies have reported 
that htt phosphorylation is associated with reduced levels of mutant htt toxicity [83, 89, 
91, 92, 97-99]. Mutating Thr3 to aspartate to mimic phosphorylation enhances the 
propensity of htt to aggregate in cultured cells and resulted in reduced lethality and 
neurodegeneration in Drosophila models of HD [89]. Htt containing phospho-serine 
residues at 13 and 16 aggregate in a similar fashion to serine to aspartate phosphomimetic 
mutations, demonstrating that serine phosphomimetic mutations are valid mimics for 
studying the impact of htt phosphorylation on aggregation. Using a variety of 
combinations of serine phosphorylation mimics, it was established that serine to aspartate 
mutations significantly slows the formation htt aggregates and reduces the stability of the 
fibril structure [43, 92]. When Ser13 and Ser16 were mutated to aspartate in the Nt
17
 
domain of transgenic mice that expresses full length htt with 97Q, visible htt inclusions 
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within the brain were reduced, and HD–like behavioral phenotypes were reduced at 12 
months of age [92]. Altering the phosphorylation state of htt (specifically at Ser13) 
indirectly can also impact expanded htt related toxicity, as casein kinase 2 inhibitors 
reduced Ser13 phosphorylation with a subsequent enhancement of htt-related toxicity in 
high content live cell screenings [100]. Furthermore, ganglioside, GM1, triggers htt 
phosphorylation at Ser13 and Ser16, diminishing htt toxicity while restoring normal 
motor behavior in transgenic mice [90]. Collectively, this finding further support the 
notion that Nt
17
 plays an important role in htt aggregation and, more specifically, that 
altering the phosphorylation state of Nt
17
 may be a viable therapeutic strategy.  
 Htt can also undergo SUMOylation, ubiquitination, and acetylation on specific 
lysine residues within Nt
17
. These potential sites include lysine residues at position 6, 9, 
and 15. SUMOylation, specifically, has been implicated in both cell and animal models to 
be involved in HD pathogenesis [81, 87]. SUMOylation at lysine 6 (K6) and lysine 9 
(K9) stabilizes htt exon1 fragments, reducing aggregation in cultured cells and 
exacerbating toxicity in Drosophila HD models [81]. Rhes, a small G protein, 
preferentially binds mutant htt over wild type and acts as a SUMO E3 ligase [101]. The 
subsequent SUMOylation by Rhes increases soluble levels of htt and enhances 
neurotoxicity [101]. Ubiquitination is known to compete for the same lysine residues as 
SUMOylation, but functionally, it is associated with tagging proteins for degradation by 
the ubiquitin proteasome system (UPS), thereby reducing the toxicity of the mutant htt 
[102]. However, the presence of ubiquitin in neuronal intranuclear inclusions in the HD 
striatum and cortex shows that the detoxification mechanisms by ubiquitination is 
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K9 is appreciably acetylated in mammalian cell lysates [103]. While the role of K9 
acetylation has not yet been fully evaluated, acetylation of lysine 444 (K444) has been 
implicated in autophagic removal of mutant htt for clearance leading to neuroprotection 
in C.elegans HD model [93]. Perhaps, acetylation within Nt
17
 plays a similar role, but the 
impact of acetylation within Nt
17
 on aggregation and toxicity of htt has not been fully 
elucidated. 
Finally, PTMs can occur in tandem, directly affecting other PTMs. For instance, 
htt SUMOylation can be modulated by phosphorylation, explaining why Ser13 and Ser16 
phosphomimics in htt were found to modulate SUMO-1 modification both in cells and in 
vivo [91, 92]. SUMOylation is a transient process, and Nt
17
 lysines are predicted as low 
probability SUMO sites. Therefore, one way to enhance Nt17 SUMO-1 modification is to 
use serine phosphomimetic mutants [87]. Interestingly, these phosphomimics also 
promote K6 htt SUMOylation, which may represent one way to regulate K9 acetylation 
[87]. SUMOylation and ubiquitination can also influence each other by competing for the 
same Nt
17
 lysine 6, 9 and 15 [81] , implying that one modification could be used to 
control or enhance the other. Understanding how Nt
17
 PTMs impact htt and modulate 
each other could lead to therapeutic intervention with the potential implications to HD. 
Here, the acetylation of htt and its role in modulating htt aggregation will be presented. 
1.4.4 Nt
17
mediates htt/lipid interactions with potential implications for 
 toxicity. 
 Another potential role of Nt
17
 in htt-related toxicity is that Nt
17
 directly dictates 
whether, and to what extent, toxic protein aggregates interact with cellular and 
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subcellular compartments, such as organelles. These interactions would be mediated by 
Nt
17
's ability to bind membranes comprised predominately of lipids and could play an 
important role in htt trafficking. These membranes may also be direct targets of htt 
aggregates, that is, htt aggregates may alter membrane structure and stability as part of a 
molecular mechanism of toxicity. A considerable number of observations directly and 
indirectly support such notions. Htt has been implicated in the transport of lipid vesicles 
(endocytic,
 
synaptic or lysosomal), especially along microtubules [104-107]. 
Approximately 50% of endogenous htt were found to partitions with membranes after 
subcellular fractionation of neuron-like clonal striatal cells [108]. In vitro experiments 
have shown that brain lipids large unilamellar vesicles (LUV) interacted with htt exon1 
fragments and enhanced fibril formation of htt aggregates [109], highlighting the 
importance of Nt
17
 in lipid/protein binding. Expanded polyQ-conferred nuclear 
localization of htt appears to require additional htt sequences such as Nt
17
 [110], and Nt
17
 
itself has been implicated to function as a nuclear export signal [111]. Htt also associates 
with acidic phospholipids [112] which could play a role in nucleating aggregation. 
Furthermore, htt localizes to brain membrane fractions [113] which are primarily 
comprised of lipids.  
 There are a variety of membrane-associated functions attributable to htt in which 
the lipid-binding properties of Nt
17
 may play a role. These functions include cellular 
adhesion [114], motility [115, 116], cholesterol and energy homeostasis [117], and as a 
molecular scaffold for coordination of membrane and cytoskeletal communication 
[112] as well as facilitating microtubule-dependent vesicle transport [118]. Nt
17
 facilitates 
the trafficking of htt exon 1 to membranes associated with the ER, autophagic vacuoles, 
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mitochondria, and Golgi [39, 119]. Membrane curvature sensing, facilitated by AH 
structural characteristics of Nt
17
, may play a mechanistic role in these functions [60]. 
Additional evidence that Nt
17
 directly interacts with lipid membranes was provided by the 
observation that the binding of htt exon 1 to large unilamellar vesicles composed of 
phosphatidylcholines (PC) or a mixture of PC and phosphatidylserines (PS) enhanced the 
helical content of Nt
17
 [39]. These changes in helical content were blocked by changing 
the eighth residue of Nt
17
 to a proline [39]. Through solid state nuclear magnetic 
resonance structural analysis studies, Nt
17
 of htt has been found to have an amphipathic 
alpha helical structure with membrane binding properties [120, 121], where it transition 
structurally from random-coil in solution to an α-helical structure upon binding lipid 
bilayers. Nt
17
 in synthetic polyQ peptides was required for synthetic polyQ peptides to 
bind model brain lipid extract membranes [53]. Synthetic polyQ peptides with a variety 
of flanking sequences readily form fibrils in solution or solid surfaces such as mica, but 
lipid membranes stabilize discrete oligomeric aggregates of polyQ peptides that contain 
Nt
17
 [53]. However, both Nt
17
 and a C-terminal polyP domain were required for polyQ 
peptides to destabilize membrane structure, leading to leakage. Computational studies 
further support the important role of Nt
17
 in htt/lipid interactions and also provide 
evidence that the presence of both Nt
17
 and polyP enhance the interaction of htt with 
bilayers [63]. The cooperative effect of Nt
17
 and the polyP domain in disrupting 
membranes may be particularly important in light of observed interactions between these 
two domains in a cellular environment that is altered with increasing polyQ length [122]. 
The binding and disruption of lipid membranes by full htt exon 1 constructs can be 
1. Introduction 
  16 
 
partially inhibited by the addition of N-terminal tags, further supporting a prominent role 
of Nt
17
 in these phenomena [123].  
 In terms of a potential role in htt-related toxic mechanisms, the accumulation of 
monomeric htt and/or prefibrillar aggregates directly binding lipid membranes has been 
shown to disrupt bilayer integrity and to induce mechanical changes in the membrane 
[123, 124]. Another factor regulating the interaction of htt with lipid membranes 
mediated by Nt
17
 are the previously discussed PTMs, which are known to be involved in 
htt translocating to specific organelles [39, 125]. Additional affinity-based components 
for the interaction of other AHs with lipid bilayers also play a role, including 
electrostatics [126, 127], partitioning of lipid components [128-130], or the presence of 
other specific recognition motifs [131, 132]. The availability of Nt
17
 to interact with lipid 
membranes could also play an important role in cell to cell transport of htt aggregates. 
This may prove particularly important with the realization that there are non-cell-
autonomous toxic effects associated with HD [133-137]. The study of htt/lipid membrane 
interaction may contribute to the understanding of the mechanism of pathology of HD. 
1.5 Lipid Composition in huntingtin/lipid interaction 
 As previously discussed, htt is found highly associated with a variety of cellular 
and subcellular membranes that are predominantly comprised of lipids, consisting of 
physiological composition of cholesterol, sphingomyelin and ganglioside (GM1). 
Cholesterol affects the functional properties of membrane-resident proteins (ion channels 
and transmitter receptors), as well as plays a role in signal transduction, synaptogenesis, 
and neurotransmitter release [138-140]. Abnormalities in cholesterol metabolism and 
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homeostasis have been observed in cellular and animal models of HD, as well as in HD 
patient tissues [141-143]. However, the specifics of altered cholesterol content associated 
with HD remains controversial. It has also been demonstrated that reduced synthesis of a 
gangliosides, GM1, occurs in the cells and brains of HD patients, leading to increased 
programmed cell death. However, administration of GM1by continuous infusion into the 
ventricles of brains of HD mice results in complete reversal of motor defects in these 
mice [144], and increased in phosphorylation at Ser13 and Ser16 [90], suggesting that the 
mechanism of GM1 neuroprotection could be phosphorylation of htt. While the 
importance of htt aggregation in HD has long been appreciated, the impact of specific 
lipid components, such as cholesterol, GM1 and sphingomyelin, on modulating htt 
aggregation is poorly understood. The final part of this thesis involves evaluating how 
exogenously GM1, sphingomyelin, added and cholesterol, affects htt/lipid membranes 
interaction. 
 
1.6 Dissertation Outline and Study Rationale  
 Although it has been over two decades since the discovery of the IT15 gene, great 
strides have been made in understanding HD, but there is still no therapeutics that either 
cures or stops disease progression. Based on this and the ongoing discussion on the role 
of lipid membranes and posttranslational modification as potential modulators of htt 
aggregation the following topics are addressed in this dissertation:  
(1) A variety of protein motifs play a critical role in sensing and targeting specific 
physical properties of membranes. Htt, in particular, interacts with a variety of 
membranous structures within the cell, and Nt
17
 of htt is an AH lipid-binding 
1. Introduction 
  18 
 
domain. AHs are also known to detect membrane curvature. Flat supported lipid 
bilayers are commonly used as model membranes for AFM studies of protein 
aggregation; however, these supported bilayers usually lack curvature. Chapters 
2 and 3 addresses if htt exon1 preferentially binds curved membranes by 
developing and validating a system of a model supported lipid bilayer with both 
flat and curved regions. This system is exposed to a truncated htt peptide to 
determine if curvature plays a role in the interaction of htt with lipid membranes. 
(2) Nt17 influences the aggregation of N-terminal fragments of htt and their direct 
interactions with lipid membranes. Furthermore, PTMs within Nt
17
 have a 
profound effect on the toxicity associated with mutant htt containing expanded 
polyQ domains. However, the impact of acetylation of Nt
17 
on modulating htt 
aggregation and its interactions with lipid bilayers is poorly understood. Chapter 
4 investigates the influence of acetylation of Nt
17
on htt aggregation on lipid 
bilayers. 
(3) Finally, the relevance of htt aggregation in HD has been studied extensively, and 
lipids play important roles on the aggregation of a variety of htt fragments.  
However, the role and impact of specific lipid components, such as cholesterol, 
sphingomyelin and GM1, on modulating htt aggregation is not quite understood. 
Abnormalities in cholesterol homeostasis having been implicated in HD, and 
direct administration of  GM1 into yeast artificial chromosome (YAC) mice 
model expressing the full length mutant huntingtin was found to reduce 
pathology. Chapter 5 sought to understand the role of these specific lipid 
components on htt aggregation with the potential implications to HD. 
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1.7 Atomic Force Microscopy 
 To address these questions, a number of techniques including, AFM were used to 
study htt/lipid interaction. Htt forms a variety of nanoscale aggregates through a complex 
pathway that involve oligomers, off-pathway aggregates and fibrils (as previously shown 
in Fig. 1). Due to the complexity of the aggregation pathway and nanoscale size of these 
aggregates, AFM has emerged as a robust and versatile tool for distinguishing and 
characterizing the morphology of disease-related protein aggregates [145-147]. AFM can 
be operated both in air and solution, allowing the dynamic tracking of aggregates under 
near physiological conditions, at nanoscale resolution [29, 145, 148-152]. Since its 
inception by Binning and Rohrer [153], AFM has become an invaluable tool for three-
dimensional imaging as well as measuring structural features of aggregates [124, 154]. 
As shown in Fig. 3, AFM measures the vertical displacement of a cantilever with an 
ultra-sharp probe that interacts with the sample surfaces. A laser is reflected off the back 
of the cantilever into a photosensitive photodiode detector. The tip is brought close to the 
sample surface, and the interaction tip/sample forces cause the deflection of the 
cantilever. This deflection is measured using an optical lever provided by reflecting a 
laser off of the cantilever onto a photodiode. The piezo scanner enables the cantilever to 
scan back and forth across the sample. Images are generated by raster scanning the tip 
across the sample surface.  The feedback loop helps maintain constant deflection or 
amplitude while imaging. 
 There are three main modes of AFM, namely contact, tapping/intermittent, and 
non-contact mode. In contact mode, commonly described as the most direct AFM mode, 
the probe is brought in direct contact with the surface and the deflection of the cantilever 
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is monitored. This AFM mode allows for fast scanning and is good for imaging hard 
samples. However, it is heavily influenced by frictional and adhesive forces [155], and as 
such considerable amount of lateral and shear forces are generated, causing damage to 
soft , biological samples [156] .  
 In noncontact AFM, the probe does not “touch” the surface but it oscillates above 
the surface during scanning. As the tip approaches the surface, the forces between the tip 
and the surface (as shown in Fig. 3) change the amplitude of the cantilever’s resonant 
vibration. In tapping mode, the cantilever is harmonically oscillated near its resonance 
frequency, ωο, by a piezoelectric bimorph element mounted near the cantilever root. The 
probe tip is placed in close proximity to the sample surface and allowed to intermittently 
Figure 3. Basic schematic illustration of an AFM. The ultra-sharp tip is brought in 
close contact with the surface, causing the deflection of the cantilever. The defection is 
measured by the photodiode, and together with  the feedback loop and controller, three-
dimensional topographical images of surfaces with nanoscale resolution can be obtained 
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contact the sample, leading to a decrease of the cantilever oscillation amplitude from the 
“free” amplitude, Ao, to a tapping amplitude, A [157, 158]. Owing to its ability to 
minimize potential damage to delicate, biological samples, tapping mode AFM was used 
for the studies presented in this dissertation. 
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 Tapping mode atomic force microscopy (TMAFM) has become a useful method 
to obtain physical insights into the formation of toxic protein aggregates associated with 
amyloid diseases on membranes. However, recent advances in reconstructing the time-
resolved tip/sample force during the imaging process have provided access to information 
relating to the mechanical properties of these surfaces. The ability to directly image and 
measure changes in mechanical properties of lipid bilayers associated with exposure to 
amyloid-forming peptides in a “quasi” real-time fashion can provide new insights that are 
exceedingly difficult to obtain using other traditional methods. However, the absence of 
membrane curvature, which can heavily influence the interaction of proteins at lipid 
interfaces, is one of the several limitations associated with using flat, supported bilayers 
as model surfaces. I, therefore, developed model lipid bilayer systems in which the 
underlying solid support is comprised of flat and curved regions to induce regions of 
curvature in the bilayer. To accomplish this, 50 nm silica nanoparticles were deposited on 
a silicon substrate coated with poly-L-lysine. This substrate was exposed to total brain 
lipid extract (TBLE) vesicles, which can fuse on surfaces to form lipid bilayers. Using an 
AFM based, force reconstruction technique; scanning probe acceleration microscopy 
                                                          
This chapter is based on the works: 
1
 Recovering Time-Resolved Imaging Forces in Solution by Scanning Probe Acceleration Microscopy: 
Theory and Application in Surface Science Tools for Nanomaterials Characterization. 
2
 Curvature enhances binding and aggregation of huntingtin at lipid membranes. 
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(SPAM), to measure changes in the mechanical properties of the lipid bilayers, the 
formation of supported bilayer on the surface that contained flat and curved regions was 
confirmed. This chapter gives a detailed description of the principles of the SPAM 




 TMAFM, [1] a widely used dynamic scanning probe technique, obtains 
topography images of surfaces by monitoring the oscillation amplitude of a cantilever 
integrated with an ultrasharp probe tip. In this imaging mode, the cantilever is commonly 
driven near its resonance frequency, ωο, by a piezoelectric bimorph element mounted 
near the cantilever root. The probe tip is placed in close proximity to the sample surface 
and allowed to intermittently contact the sample, leading to a decrease of the cantilever 
oscillation amplitude from the “free” amplitude, Ao, to a tapping amplitude, A [2, 3]. For 
rigid surfaces, the cantilever oscillation amplitude decreases linearly as the distance 
between the tip and the sample, Do, becomes smaller. As a result, surface topography is 
mapped by raster scanning the probe across the surface while using a feedback loop to 
continuously adjust the vertical (in the z direction) extension of a piezoelectric scanner to 
maintain a constant tapping amplitude or set-point ratio,  s = A/Ao. 
 There is significant interest in using TMAFM to simultaneously map topography 
and mechanical properties of surfaces and a variety of methods have been developed 
toward achieving this goal. While monitoring the phase of the cantilever in tapping mode 
is a common method to acquire some insight into the mechanical properties of surfaces, 
[4, 5] such images can be difficult to interpret due to various causes of energy dissipation, 
including capillary forces, [6] viscoelasticity of the sample, [7] cross talk with 
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topography, [8] and frictional forces associated with the tilt of the cantilever and/or 
surface [9]. Furthermore, the phase behavior of the cantilever becomes increasingly 
complicated when imaging in solution. For example, it has been demonstrated that the 
phase contrast associated with soft cantilevers imaging in solution can arise from either 
(i) energy propagation during the tapping event that excites higher eigenmodes of the 
cantilever mediated by conservative short-range interactions, or (ii) tip/sample energy 
dissipation [10].  
 A more straight-forward way to gain insight into sample mechanics is by 
obtaining the time-resolved force interaction between the surface and the tip during 
standard TMAFM operation. The first successful reconstruction of time-resolved 
tip/sample forces in a TMAFM experiment was accomplished by taking the inverse 
Fourier transform of the Fourier-transformed cantilever trajectory divided by its transfer 
function [11]. Since then, a variety of other methods have been developed that are 
capable of obtaining time-resolved tip/sample forces and construct images based on these 
forces [12-19].  
 There are several experimental advantages to using tapping forces as a method to 
map mechanical properties of surfaces. Due to their basis in the tapping mode, such 
methods offer high spatial resolution and are relatively nondestructive. Other traditional 
AFM techniques used to measure and/or map mechanical properties of surfaces (i.e., 
force volume imaging and nanoindentation) often require large deformation of soft 
samples, leading to decreased spatial resolution and possibly irreversible sample damage, 
whereas tapping mode forces are adaptive to changes in surfaces properties. As scan rates 
used for simple tapping mode AFM imaging are typically much faster than other methods 
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, the mapping of surface properties can be accomplished in a timelier manner. This, 
perhaps, could provide the ability to probe dynamic changes in a surface's mechanical 
properties in response to some external stimulus or environmental change.  
 The laboratory of Dr. Tomasz Kowalewski at Carnegie Mellon University, 
developed a method to recover the time-resolved tip/sample force in TMAFM while 
operated in aqueous solution is scanning probe acceleration microscopy (SPAM) (Fig. 1) 
[14]. The underlying principle behind SPAM is that the cantilever in TMAFM acts as an 
accelerometer, which can be used to extract tip-sample forces during standard tapping 
mode operation by calculating the second derivative of the cantilever deflection signal. 
Figure 1. SPAM is a method for reconstructing the time-resolved tip/sample forces 
associated with TMAFM imaging in solution. In this example, (a) a mica substrate 
with small supported lipid bilayer patch is imaged to acquire the surface topography 
while the entire cantilever deflection signal is captured. (b) The deflection trajectory of 
the cantilever is filtered using a "comb-filter" based on Fourier transforms, and the 
second derivative of the trajectory is used to reconstruct the tip/sample forces. (c) 
Images are constructed based on specific features of the tip/sample force, such as the 
maximum tapping force, which can be related to surface mechanical properties.  
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Real deflection signals from TMAFM experiments contain noise that is amplified by this 
analysis. As the signal to noise ratio in most commercially available AFMs would 
overcome the ability to reconstruct the tapping force by this simple method, a means to 
filter these signals is crucial if SPAM is to be useful experimentally. This problem is 
solved by taking advantage of the fact that most of the information about the deflection 
trajectory and the tapping event is contained in higher harmonic frequencies associated 
with the drive, [11, 20, 21] making it possible to filter the signal by ‘‘comb’’ filtering, 
i.e., by taking its Fourier transform and inverting it while selectively retaining only the 
intensities at integer harmonic frequencies of the drive. Such a comb filtering method 
works particularly well in fluid TMAFM because of the highly distorted character of the 
deflection signal [22-24].  
 
2.2 Numerical model of the entire imaging process of TMAFM in solution 
 To get a complete understanding of the tip/sample interaction associated with 
TMAFM, numeric simulations are often performed in which the cantilever is modeled as 
a driven damped harmonic oscillator [25], where 
 
𝐹𝑒𝑥𝑡 = 𝑚𝑒𝑓𝑓?̈? +  𝑏?̇? + 𝑘[𝑧 −  𝐷𝑜 +  𝑎𝑜 sin(𝜔𝑡)]   (1) 
 
meff is the effective mass of a cantilever, b is the damping coefficient, k is the cantilever 
spring constant, z is the position of the cantilever with respect to the surface, D0 is the 
resting position of the cantilever base, a0 is the drive oscillation amplitude, ω is the drive 
frequency, t is the time, and Fext is the tip/sample force. 
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 Although cantilever position, z, is often monitored in AFM simulations, in real 
experiments, most microscopes monitor the amplitude of the cantilever deflection, y, 
which is simply related to the position by: 
 
𝑦 = 𝑧 −  𝐷𝑜 +  𝑎𝑜 sin(𝜔𝑡).      (2) 
 
TMAFM can be operated in air or in fluids, and their major differences is in the quality 
factor (Q) of the cantilever, [23, 26] described by the following relationship 
 
𝑄 =  
𝐴𝑜
𝑎𝑜⁄         (3) 
 
where Ao is the free cantilever oscillation amplitude. In short, Q is the ratio of the energy 
stored in a system divided by the energy loss per cycle, and is typically in the range of ~ 
Figure 2. Comparison of simulated cantilever position and deflection trajectories 
in high Q and low Q systems. Simulations with high Q systems are applicable to 
TMAFM in air; there is minimal difference between the position and deflection 
trajectories. In low Q systems, which are associated with TMAFM imaging in solution, 
there are distinct differences between the position and deflection trajectories 
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200–400 in air, whereas in fluids it is only ∼1–5. This lower Q is primarily due to the 
large hydrodynamic damping associated with oscillating the cantilever in fluids. In high 
Q systems, the free cantilever oscillation amplitude is significantly larger than the drive 
oscillation amplitude. When operating TMAFM in a low Q system, the cantilever 
deflection and position trajectories differ significantly during tapping events as the drive 
amplitude is comparable to the free amplitude. As a result, a characteristic anharmonic 
distortion is produced in the deflection trajectory as the cantilever tip contacts the sample 
surface (Fig. 2b). As a result, tin modeling TMAFM in solution, it is necessary to rewrite 
the cantilever motion in terms of deflection as 
 
𝐹𝑒𝑥𝑡 = 𝑚𝑒𝑓𝑓[?̈? −  𝑎𝑜𝜔
2 sin(𝜔𝑡)] +  𝑏[𝑦 +  𝑎𝑜𝜔 cos(𝜔𝑡)] +  𝑘𝑦  (4) 
 
It should be noted there are several sources of distortion in cantilever deflection signals in 
experimental systems, including nonlinearities of the detector and electronics of the AFM 
that may need to be accounted for when comparing numerical simulations to 
experimental results.   
 In TMAFM the cantilever oscillation continuously changes the separation 
distance between the probe tip and the surface, allowing the tip to intermittently contact 
the sample during each oscillation cycle. Thus, there are two tip/sample interaction 
regimes required for modeling the time-resolved imaging force: (a) when the cantilever 
tip and sample surface are not in contact and (b) when the tip and surface make contact 
during the tapping event. For scenario (a), the separation distance between the cantilever 
tip and the sample surface, z, is greater than the interatomic distance, aDMT, and during the 
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contact portion (b), z is equal to or smaller than aDMT. For scenario (a) the force can be 
described by the Derjaguin-Landau-Verway-Overbeek (DLVO) theory; [27] however, 
because most biological experiments are performed under near physiological conditions 
in a saline buffer, the force associated with the electric double layer effect is negligible, 
resulting in a short Debye length [28]. Thus for simplicity, the non-contact force can be 
approximated using the van der Waals interaction between a sphere (the cantilever tip) 
and a flat surface [27] 
 
𝐹𝑒𝑥𝑡 =  −
𝐻𝑅𝑡𝑖𝑝
6𝑧2
   𝑓𝑜𝑟 𝑧 >  𝑎𝐷𝑀𝑇      (5) 
 
where H is the Hamaker constant and Rtip is the tip radius [29]. For scenario (b), the 
tip/sample force interaction can be described using a Derjaguin-Muller-Toporov (DMT) 
potential,  
 
𝐹𝑒𝑥𝑡 =  
4
3𝜅𝑒𝑓𝑓
√𝑅𝑡𝑖𝑝(𝑎𝐷𝑀𝑇 −  𝑧)
3
2⁄ −  
𝐻𝑅𝑡𝑖𝑝
6𝑎𝐷𝑀𝑇
2   𝑓𝑜𝑟 𝑧 ≤  𝑎𝐷𝑀𝑇  (6) 
where 








        (7) 
 
where E is the Young's modulus and ν is the Poisson coefficient of the tip or sample.   
 In addition, a feedback loop equipped with an integral gain can be incorporated 
into this numerical model to simulate the entire TMAFM imaging process. 
Implementation of a feedback loop can be accomplished by systematically determining 
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the cantilever amplitude for each oscillation cycle, direct comparison of this amplitude to 
a predetermined set-point amplitude, and adjusting the tip/surface separation distance to 
maintain the set-point amplitude. In this way, a simulated trace of the surface, which is 
simply the required correction in tip/surface separation distance, can be obtained for 
different model surface topographies. Combined with the ability to change the values of 
the Hamaker constant and/or surface Young’s modulus, simulations of imaging a wide 
array of surfaces with TMAFM can be performed to fully understand how the time-
resolved tip/sample force responds to surface properties.   
 
2.3 Basic principles underlying SPAM 
 Equation 4 above can be rearranged to show that that the acceleration of the 
cantilever is directly related to the tip/sample force scaled by the effective mass of the 
cantilever. 
 
?̈? =  
1
𝑚𝑒𝑓𝑓
[𝐹𝑒𝑥𝑡 −  𝑏?̇? −  𝑘𝑦 +  𝑚𝑒𝑓𝑓𝜔
2𝑎𝑜 sin(𝜔𝑡) −  𝑏𝑎𝑜𝜔 cos(𝜔𝑡)].  (8) 
 
This suggests that by taking the second derivative of the measured deflection signal the 
time-resolved tip/sample force can be recovered. In its simplest form, this process 
amounts to treating the cantilever as a local accelerometer that can be raster scanned 
across a surface. In this way, topographic and tip/sample force information can be 
obtained in one experiment simultaneously. This is the basis for SPAM. The last four 
terms of Equation 8 are all related to the action of driving the cantilever, and as a result, 
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oscillate at the drive frequency. This allows these extraneous terms to be easily 
distinguished from the tip/sample force, or even filtered out.  
 As previously mentioned, real cantilever deflection trajectories contain noise. The 
deflection trajectory of the cantilever can be filtered using a Fourier transform based 
harmonic comb filter. In this process, a sliding window Fourier transform is performed 
on the cantilever deflection signal, only intensities in the resulting power spectrum 
corresponding to integer harmonic frequencies of the drive are kept, and these are used to 
reconstruct a deflection signal, yrec(t), by an inverse Fourier transform based on the 
equation 
 
𝑦𝑟𝑒𝑐(𝑡) =  𝑓
−1[𝑦(𝜔) ∑ 𝛿(𝜔 − 𝑘𝑤𝑜𝑝𝑒𝑟)
𝑁
𝑘=1 ]         (9) 
 
where δ is Dirac's delta function, ωoper is the operating frequency, and N is the highest 
harmonic distinguishable about the noise level. The effectiveness of the use of the comb 
filter to accurately reconstruct the deflection trajectory requires a sufficient number of 
harmonics, typically more than 18, to be above the noise level in the power spectrum. As 
previously mentioned, TMAFM in fluids is characterized by a distinct distortion in the 
cantilever deflection trajectory associated with the tapping event, [23, 24, 26] and this 
distortion inherent in fluid TMAFM results in an adequate number of higher harmonics 
above the noise to facilitate comb filtering and reconstruction of the tip/sample tapping 
force from the second derivative (or acceleration) of the cantilever deflection signal. The 
sliding window of this filter typically contains 5-10 oscillation cycles, and the window is 
advanced one oscillation cycle at a time to maintain local information about the 
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tip/sample interaction. Nonetheless, with this ability to filter cantilever deflection 
trajectories, spatially resolved force maps can be constructed based on the second 
derivative. The extraneous terms in Equation 8 can be suppressed from the reconstructed 
force by excluding the fundamental frequency, i.e. drive frequency, from the inverse 
Fourier transform; however, excluding this frequency diminishes the accuracy of the 
recovered force by reducing its magnitude. The reconstructed trajectory obtained from 
the comb filter also loses information contained in harmonics below the noise level. 
Furthermore, it should be noted that the harmonic comb filter should only be applied to 
periodic motion of the kind commonly observed in TMAFM and is not applicable to 
motion exhibiting period doubling or aperiodic/chaotic character. .  
 
2.4 Features of the time-resolved tip/sample force are independent of surface 
topography  
 TMAFM can be used to image a wide variety of sample surfaces, with a range of 
topographical features. In TMAFM experiments, surface features may vary in height 
from sub-nanometer to several micrometers. To compare tapping mode imaging forces to 
mapping mechanical properties of surfaces, the features of the time-resolved tip/sample 
tapping force must be independent of the surface topography. 
To determine the role of surface topography on tip/sample tapping forces, simulations of 
complete TMAFM experiments can be performed to understand the impact of a variety of 
model surfaces with distinct morphologies on imaging forces (Fig. 3). Here, three model 
surfaces are presented: 1) a region with increased RMS roughness, 2) a flat step, and 3) a  
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round feature. These model surfaces represent a large number of the potential 
topographies that may be encountered in real AFM experiments. There are two features 
of the tapping force that are of interest here: (1) the maximum tapping force, Fmax, 
defined as the most positive force experienced between the cantilever tip and the sample 
surface during each cantilever oscillation cycle, and (2) the minimum tapping force, Fmin, 
defined as the most negative force experienced between the cantilever tip and the sample 
Figure 3. Simulations to determine the effect of surface topography on tip/sample 
imaging forces. A variety of surface topographies were modeled: (a) a rough surface, 
(b) a flat step, and (c) a curved feature where roughness or height was varied from 1-5 
nm. The maximum and minimum tapping forces, (d-f) and (g-i) respectively, were 
averaged over the altered surface topography and found to be independent of changes 
in surface topography. 
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surface. The size of these features can be systematically increased to determine changes 
in Fmax and Fmin associated with imaging these model surfaces. All other surface 
characteristics (such as Young's modulus, Hamaker constant, etc.) and imaging 
parameters (set-point ratio, free amplitude, cantilever spring constant, etc.) were held 
constant in these simulations. Importantly, the average Fmax and Fmin associated with 
imaging all three of these surfaces do not change as a function of the size of the feature in 
the model, as long as the feedback loop is able to maintain proper tracking of the surface. 
Fmax for the various topographies were averaged over the altered surface feature (the 
rough patch, the step, or the round feature) and had an approximate value of 25 nN for 
each type of surface and each height variation (Fig. 3d-f). The Fmin for each surface 
variation was approximately -2 nN, which was exactly the same as the flat region of the 
surface. This indicates that as long as the feedback loop is optimized, changes in the 
time-resolved tapping forces are independent of topographical features. 
 
2.5 Application of SPAM 
 Most studies utilizing SPAM have focused on supported lipid membranes as well 
as a variety of systems. Supported bilayers have a considerably lower elastic modulus 
compared commonly used surfaces such as mica and silicon, so this system provides a 
surface with a soft region (supported bilayer) and hard region (exposed mica). 
Histograms of Fmax and Fmin associated with imaging this system are distinctly bimodal,  
with each mode corresponding to either the mica or bilayer portions of surface, and 
providing excellent contrast in the reconstructed force images (Fig 4b-c). Consistent with 
the simulation results, the values of Fmax corresponding to the bilayer were lower in  
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comparison with those corresponding to mica. The magnitude of Fmin associated with 
imaging mica was larger than that for the bilayer patch, indicating that the tip adhered 
more strongly to the mica surface. Several studies have measured mechanical changes in 
supported lipid membranes using SPAM. For example, SPAM has been used to 
determine the effect of cholesterol on the modulus of lipid bilayers [30], how exposure to 
lipoprotein particles alter membrane mechanics, [31]  and how membrane disruption 
caused by a variety amyloid-forming proteins alter local mechanical properties of lipid 
bilayers [32-35]. In this chapter, SPAM was used to monitor changes in the mechanical 
properties during the formation of supported lipid bilayers with membrane curvature. 
  
 
Figure 4. SPAM imaging of a supported lipid bilayer patch on mica. (a) 
Topography image with the green line corresponding the height profile to the left. (b) 
Fmax and (c) Fmin images are presented with histograms of these respective forces for 
every tapping event presented to the left of the images. The insets zoom in on small 
areas containing small, stacked bilayer on the patch (blue arrows). 
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2.6 SPAM in the developed of supported lipid bilayers with curvature 
 Supported lipid bilayer patches on mica substrate represented the first successful 
application of the SPAM technique on an experimental system. These bilayers have a 
considerably lower elastic modulus compared to mica, so this system provides a surface 
with a soft region (supported bilayer) and hard region (exposed mica). Supported lipid 
bilayers are commonly used as model membranes for AFM studies of protein 
aggregation. However, these supported bilayers usually lack curvature. By forming a 
bilayer on top of silica nanobeads (50±10 nm) deposited on a silicon substrate, model 
supported lipid bilayers with flat and curved regions were developed for AFM studies 
(Fig. 5). The presence of the bilayer over the beads was validated by continual imaging of 
the formation of the bilayer, height measurements, and spatially resolved mechanical 
measurements of the resulting bilayer using SPAM. Interpretation of this data was 
facilitated by numerical simulations of the entire imaging process.  
 
 2.6.1 Preparation of total brain lipid extract 
 Lyophilized total brain lipid extract (TBLE) (Avanti Polar Lipids) was dissolved 
in chloroform (ACROS Organics). The chloroform was evaporated using a Vacufuge 
plus (Eppendorf) to form a thin lipid film on the bottom walls of a micro centrifuge tube. 
The TBLE was reconstituted in 10 mM Tris HCl buffer (pH 7.3) with periodic vortexing 
to a concentration of 1mg/ml. To facilitate bilayer and multilayer sheet formation, the 
lipid sample tube went through five freeze/thaw cycles by sequential immersion in liquid 
nitrogen followed by thawing at 37 
o
C in a thermomixer (Eppendorf) [36]. The lipid 
sample was then bath sonicated for 45 minutes to facilitate vesicle formation. Using the 
57 
2. SPAM: Development and validation of bilayers with membrane curvature 
hanging drop method, 15µl of 1:1 mixture of TBLE/Tris-HCl was added directly into an 
AFM fluid cell on a clean silicon substrate decorated with 50 nm silica nanoparticles 
(Polysciences, PA). The same lot of lipids was used in all experiments. 
 
2.6.2 Preparation of poly-L-lysine coated silicon substrate 
  Ultra-flat silicon wafers, type<100> (Ted Pella) were cut into 1cm x 1cm square 
sizes, and sequentially sonicated in acetone, absolute ethanol, and deionized water for 20 
minutes each. The wafers were then kept under water overnight and dried by blowing 
canned air. The clean substrates were placed under ozone for 1 hour to remove any traces 
of organic contaminants [37] from the acetone and ethanol. Once more, the wafers were 
rinsed in ultrapure water, dried with air, and placed on a hot plate at 30 
o
C to remove any 
residual solvent present. These substrates were stored in a dust free petri dish prior to use. 
A 25µl aliquot of 0.1% poly-L-lysine was evenly spread on the clean, square silicon 
substrate and placed on a hot plate at 30
o
C for 5 minutes, followed by rinsing with 1 ml 
of deionized water to remove excess unbounded poly-L-lysine molecules [38]. 
 
2.6.3 Nanoparticles deposition on silicon substrate 
 Silica nanoparticles purchased from Polysciences were diluted to the desired 
concentration of 0.010% (0.10g/L) with ultrapure water, followed by 1 hour of sonication 
prior to deposition. A 20 µl drop of silica dispersion was evenly spread on the silicon 
substrate and allowed to slowly dry at room temperature [39]. This was rinsed with 100 
µl of ultrapure water to remove any excess, loosely bound beads on the surface followed 
by air drying, and stored in a dust free environment prior to AFM experiments. 
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2.6.4 In situ AFM and SPAM imaging conditions 
 A Nanoscope V Multimode AFM (Veeco,Santa Barbara,CA) equipped with a 
tapping mode fluid cell and an O ring was used to perform in situ AFM experiments. The 
silicon substrates with beads were scanned using a rectangular shaped silicon nitride 
cantilevers (Vista probes) with a nominal spring constant of 0.1 N/m. Typical scan rates 
ranged from 1-2 Hz, and drive frequencies of 5 - 6 kHz were used. For scanning probe 
acceleration microscopy (SPAM) analysis,[40] topography images were captured at 
512x128 pixel resolution. While the topography images were being captured, the 
cantilever deflection trajectories were simultaneously captured with a signal access 
module (Veeco) and CompuScope 14100 data acquisition card (Gage, Lachine, QC) at 
2.5 MS/s and 14 bit resolution with a range of 2 V. The captured cantilever trajectories 
were filtered with a sliding-window Fourier transform-based harmonic comb filter, and 
the second derivatives of the filtered cantilever deflection trajectories were taken and 
multiplied by the effective mass, meff, of the cantilever to obtain the time-resolved-based 
tapping force between the tip and sample. To understand the tip/sample forces, we carried 
out numerical simulations in which the cantilever was modeled as a driven damped 
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2.7 Results 




Figure 5. Time-lapse AFM images taken in solution of a TBLE bilayer forming 
over silica beads immobilized on silicon. Images were taken of the surface (a) before 
exposure to lipid vesicles and (b−d) at 30 min increments after injection of lipid 
vesicles. The blue arrow in panel (a) indicates a silica bead that was knocked off of the 
surface by the imaging process and does not appear in subsequent images. The red 
arrow in panel c indicates a lipid vesicle that did not completely flattened and fused 
into the bilayer. A zoomed-in AFM image was taken at (e) 30 min after injection of 
TBLE into the fluid cell with the black line corresponding to the (f) height profile. (g) 
Histogram of height measurements associated with each pixel in the image presented in 
panel e demonstrating the height of the bilayer. 
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 To provide a substrate capable of inducing well-defined, local regions of 
curvature in a supported bilayer, the strategy of using silica beads (diameter of 50 ± 10 
nm) that were immobilized on clean silicon surfaces pre-treated with 0.1% poly-L-lysine 
as substrates was employed. These substrates were subsequently exposed to vesicles 
comprised of TBLE, resulting in the formation of a lipid bilayer on the surface via the 
process of vesicles flattening and fusing on the surface (Fig. 5b-c). This strategy would 
provide both curved and flat bilayers in the same system, and would allow for the direct 
tracking of htt aggregation on these two distinct regions by AFM imaging in solution. 
While the beads were found to be firmly attached to the surface, the process of acquiring 
AFM images and/or injecting solutions containing vesicle into the fluid cell did result in 
rare instances where a bead was displaced from the surface (Fig. 5a, blue arrow). The 
formation of the lipid bilayer on the flat portions of the substrate could be tracked by 
continuous AFM imaging of the scan area, and smooth bilayer completely covered these 
flat regions of the surface typically within ~90 minutes. At intermediate time points, the 
thickness of the bilayer could be determined from analysis of AFM height images. The 
supported bilayer above the flat silicon substrate was 7.3 ± 0.4 nm, as demonstrated by 
height profiles and histograms of the height associated with every pixel in the image (Fig. 
5e-g).  
 Despite the obvious formation of lipid bilayer on the flat portions of the substrate, 
there are two primary ways the bilayer can form to accommodate the presence of the 
immobilized bead: 1) by forming a pore around the periphery of the bead or 2) by 
forming a bilayer over the top of the bead, thus enveloping it (Fig. 6). Both scenarios 
have been observed in the literature [39]. The first scenario is not useful for this study, as 
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it would not result in a curved model bilayer; however, the second scenario would 
provide such a surface. As a result, the formation of the bilayer forming over the top of 
the beads, thus encapsulating them, needed to be verified. Previous studies used 
comparison of the height of the bead and phase imaging before and after addition of lipid 
to determine of the bilayer formed over the bead [39]. The logic behind this approach is 
that if the bilayer forms on the flat substrate and on top of the bead that there would be no 
apparent change in height of the bead. If the bilayer formed a pore around the bead, than 
the observed bead height would be decreased by the thickness of the bilayer. Therefore, 
the average height of the exact same beads immobilized on the silicon surface were 
compared before addition of any lipid and after the bilayer appeared to have completely 
covered the flat portions of the substrate. There was an observed decrease of 2.9 nm in 
the average bead height associated with the presence of the lipid bilayer. As the bilayer 
on the flat region was known to have an average height of 7.3 nm, this smaller observed 
height suggests that some form of lipid did indeed deposit over the top of the beads, but 
that there is also something physically different between the lipid on top of the bead and 
the flat portion of the substrate.  
 
Figure 6. Schematics demonstrating two potential ways the lipid bilayer could be 
arranged with respect to the beads: (a) the bilayer could form along the surface but 
not over the bead or (b) the bilayer could form over the top of the bead, which would 
result in different packing associated with the forced geometry (insets). 
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2.7.2 Validating bilayer formation on beads using imaging forces.  
 Analysis of the time-resolved imaging forces associated with tapping mode AFM 
was performed in order to provide an understanding of why this small height different 
was observed and providing further validation that bilayer had indeed formed over the 
top of the bead. These imaging forces have been demonstrated to be highly dependent on 
surface mechanical properties, and in particular, the maximum tapping force (Fmax), 
defined as the peak or largest force occurring between the tip and surface during a single 
tapping event, can be used as an indirect measure of the compression or Young's modulus 
of a sample. While AFM topography images were obtained of the beads on silicon before 
and after the formation of a lipid bilayer, the entire cantilever deflection signal was 
captured and processed to recover the time-resolved tip/sample tapping force by SPAM. 
In this way, the tapping forces can be associated with specific features in the topography 
image and used to make surface maps of mechanical properties. To aid in interpreting 
these force maps and directly relating them to the observed height measurements of the 
beads, several numerical simulations of the complete tapping mode AFM imaging 
process in solution were performed [33, 36, 41]. 
 
 The rigidity of a surface can be modeled by varying the Young's modulus of the 
sample in equation 7. A series of simulations were run with Young's modulus values of 
the model surface ranging from 0.5 to 100 GPa (Fig. 7). All other imaging parameters 
were held constant, e.g., cantilever free amplitude, spring constant, and set-point ratio, 
when imaging these model surfaces. As a result, the total tip/sample imaging force over 
an entire cantilever oscillation cycle was constant; however, this force was distributed  
63 
2. SPAM: Development and validation of bilayers with membrane curvature 
 
differently over the entire tapping event (Fig. 7a). As the surface became increasingly 
more compliant, the contact time between the tip and surface increases, resulting in the 
imaging force being distributed over this longer contact time with a corresponding 
decrease in the Fmax associated with the tapping event. This decrease in Fmax with smaller 
values of surface Young's modulus followed a power law dependence (Fig. 7b). For any 
given set of imaging parameters, this power law dependence between Fmax and the 
surface Young's modulus was observed; although, the magnitude of the forces would 
vary. For example, increasing the cantilever spring constant resulted in larger values of 
Fmax , but for any given spring constant, the power law dependence between Fmax and 
Young's modulus was observed (Fig. 7b). This demonstrates that for any given set of 
imaging parameters that Fmax can be used as a way to compare the relative rigidity of 
features within an AFM image. 
 
 
Figure 7. Tapping mode AFM simulations demonstrate the relationship between 
imaging forces and surface mechanical properties. (a) Simulated time-resolved 
tip/sample forces associated with tapping mode AFM imaging on surfaces with 
various values of Young’s modulus. (b) Maximum tapping force as a function of the 
surface Young’s modulus for cantilevers with different spring constants. 
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 Next, numerical simulations of imaging a bead deposited on a surface via tapping 
mode AFM in solution were performed. The model surface used in these simulations was 
125 nm long, and contained a 50 nm wide curved region that was 50 nm in height and 
flanked by flat regions (Fig. 8a). The Young's modulus of the flat and curved regions of 
the model surface could be independently altered. First, simulations were performed to 
determine if changes in Fmax could potentially be associated with the curvature associated 
with the beads. When the Young's modulus of the flat and curved regions of the model 
surface was equal, there was no observed change in Fmax (Fig. 8b). When the Young's  
Figure 8. Tapping mode AFM simulations demonstrate the effect of Young's 
modulus on the measured height of a 50 nm bead. (a) The model surface used in 
these simulations consisted of a 125 nm long surface that contained 50 nm bead (radius 
of 25 nm). (b) Comparison of Fmax associated with flat and curved substrates of the 
same Young's modulus. (c) Simulated height traces of a bead with different values of 
Young's modulus sitting on a substrate with a Young's modulus of 100 GPa. (d) 
Simulated height traces of a bead with different values of Young's modulus sitting on a 
substrate with a Young's modulus of 1 GPa. In both (c) and (d), the location of the bead 
is highlighted with gray shading and the true bead height is indicated by the dashed 
line. 
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modulus differed between the flat and curved regions, Fmax changed as would be 
predicted based on the power law dependence, that is, the softer region was always 
associated with a smaller Fmax regardless if this corresponded to the flat or curved region 
of the surface. Next, the measured height of the model bead with varying values of 
Young's modulus (ranging from 0.5 GPa to 100 GPa) with respect to the flat region of the 
surface, which had a Young's modulus of 100 GPa (Fig. 8c) or 1.0 GPa (Fig. 8d), was 
determined. When the bead and flat regions of the model surface had the same Young's 
modulus, the measured height of the bead was the same as the true height of the bead, i.e. 
50 nm. Whenever the flat region of the model surface was more rigid compared to the 
bead, the observed height was smaller compared to the true height of the bead with the 
observed height becoming increasingly smaller with lower values of Young's modulus. If 
the flat portion of the surface was softer than the bead, the observed height of the bead 
became systematically larger than the true height as the Young's modulus of the bead 
Figure 9.  Maximum forces associated with imaging the surfaces confirm the 
presence of lipid bilayers covering the beads. Height and the corresponding Fmax 
images of beads deposited on silicon substrates (a) before addition of lipid vesicles, and 
(b) after the formation of a lipid bilayer are presented.  
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increased. The deviation of the height of the bead from the true height is a result of the 
applied force associated with the imaging process compressing the softer regions of the 
surface to a greater extent, which forms the basis of compliance based contrast in AFM. 
Keeping the results of the AFM simulations in mind and to confirm the presence of a 
lipid bilayer on top of the beads, the relative local rigidity of actual surfaces was mapped 
before and after the formation of the lipid bilayer. This was accomplished by 
reconstructing the time-resolved tip/sample force associated with every tapping event 
while obtaining AFM images by SPAM, allowing Fmax (and thus rigidity) to be correlated 
to specific regions of the surface. There was stark contrast in the Fmax image between 
beads and bare silicon (Fig. 9). The magnitude of the force indicated that the beads were 
softer compared to the bare substrate, which is consistent with the literature values of 
Young's modulus for the two materials. The bulk Young's modulus of silica is ~ 73 GPa, 
and the Young's modulus of silicon is typically >100 GPa. After a bilayer was observed 
to completely form on the flat portion of the substrate, the magnitude of Fmax 
corresponding to the location of the beads was smaller than the surrounding bilayer. As 
supported lipid bilayers have a Young's modulus on the order of 1 GPa or smaller, the 
Fmax associated with an exposed silica bead would be larger. Thus, observed Fmax 
suggests that a lipid bilayer covered the beads and that the curved bilayers on top of 
beads were more compliant (smaller Young's modulus) than the flat supported bilayers. 
Based on the simulations, the increased compliance would result in a smaller measured 
height of the bead as the tip compresses the curved bilayer to a larger extent compared to 
the flat bilayer. The reduced Young's modulus of bilayers on top of the beads was most 
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 While tapping mode AFM in solution is widely used to study morphological and 
mechanical properties of supported lipid bilayers, one of the limitations associated with 
comparing these results to physiologically relevant membranes is the lack of membrane 
curvature associated with such systems. A potential method to induce curvature in 
supported lipid membranes is introducing local curvature in the substrate. This was 
accomplished by depositing silica nanobeads onto a silicon substrate, and by the process 
of vesicle fusion, formed a supported lipid bilayer that covered the flat silicon substrate 
and curved beads. Verification of the lipid bilayer forming on top of the beads was 
provided by a combination of height measurements and analysis of time-resolved 
tip/sample forces. Interpretation of both height and force analysis was aided by numerical 
simulations of the entire imaging process involving a model surface of the correct 
topography. Interestingly, Fmax revealed that not only did lipid organize on top of the 
beads, but that bilayers on top of the beads had a qualitative reduction in the Young's 
modulus compared to bilayer supported by flat regions of the substrate, which was 
consistent with alterations in lipid packing associated with induced curvature [42, 43]. 
Collectively, these results demonstrate that membrane curvature can significantly alter 
bilayer mechanical properties and that these changes can be detected by AFM tip/sample 
force reconstruction.  
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 With the validation that supported lipid bilayers formed over the beads, a model 
system that allowed studies to simultaneously monitor the interaction of proteins with 
curved or flat regions of a bilayer was developed. There are several advantages associated 
with such an approach. Mechanical measurements confirmed that the bilayer on top of 
the beads was mechanically, and thus structurally, different compared with the flat 
portions of the bilayer, and this is one of the advantages of using AFM for these types of 
studies. Though, TBLE was used as the lipid system, this approach should be amenable 
to various lipid systems as well. Due to the uniform size of the beads, the curved portions 
of the supported bilayer are relatively uniform. In theory, the curvature can be modified 
by changing the size of the beads; however, encapsulation of immobilized beads by a 
lipid bilayer does not occur on all bead sizes, as has been previously observed [39, 44]. 
This reinforces the importance of confirming the formation of the bilayer over the top of 
the beads, and lack of such confirmation is the main reason beads of varying size were 
not used for the studies presented here. Another caveat associated with this approach that 
should be noted is that these bilayers are still supported, and underlying substrates may 
influence the fluidity and other properties of lipid membranes.  
 
2.9 Conclusions 
 In conclusion, supported lipid bilayers with curvature may fight useful 
applications, and such can be exposed to amyloid-forming proteins to determine the 
impact of membrane curvature on protein/lipid interactions associated with diseases. It 
can also provide indispensable information on nanobeads-lipid membrane interaction, 
and cytotoxicity. 
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Huntington disease (HD) is a genetic, autosomal neurodegenerative disease caused by an 
expanded polyglutamine (polyQ) in the first exon of the huntingtin (htt) protein, 
facilitating its aggregation. Htt interacts with a variety of membranous structures within 
the cell, and the first seventeen amino acids (Nt
17
) of htt directly flanking the polyQ 
domain is an amphiphathic α-helix (AH) lipid-binding domain. AHs are also known to 
detect membrane curvature. To determine if htt exon1 preferentially bound curved 
membranes, in situ atomic force microscopy (AFM) studies were performed. Supported 
lipid bilayers are commonly used as model membranes for AFM studies of protein 
aggregation. However, these supported bilayers usually lack curvature. Supported lipid 
bilayers with curvature were developed as described in chapter 2. This model bilayer 
system was exposed to synthetic truncated htt exon1 peptide (Nt
17
Q35P10KK), and this 
peptide preferentially bound and accumulated to curved membranes, consistent with the 
ability of AHs to sense membrane curvature. 
                                                          
1
 This chapter is based on “Curvature enhances binding and aggregation of huntingtin at lipid membranes” 
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3.1 Introduction: Huntingtin’s disease and Importance of membrane curvature 
  
 Huntington's disease, a fatal neurodegenerative disease, is caused by an expansion 
of a polyglutamine (polyQ) domain in the first exon of the htt [1]. Lying near the N-
terminus of the protein, expansion of polyQ beyond a critical threshold (~35-39 repeat 
residues) directly leads to the formation of a variety of htt aggregates, i.e. oligomers and 
fibrils, with the eventual formation of inclusion bodies in HD brain tissues [2]. The age of 
onset and severity of disease are strongly correlated with the length of the polyQ 
expansion [3]. Full length htt is over 3144 amino acids in size; however, a large number 
of truncated htt products are produced in vivo via proteolysis,[4-6] and several lines of 
evidence suggest that the first exon of htt may play an important role in HD. For 
example, the expression of htt exon1 with an expanded polyQ tract causes a progressive 
neurological phenotype in transgenic mice [2, 7], and N-terminal fragments comparable 
to exon1 are detected in knock-in mouse models of HD that express full-length htt [2, 7] 
and in HD patients [5]. 
 Structural analysis of the first 17 amino acids of htt exon1 (Nt
17
) directly 
preceding the polyQ tract suggests it functions as a lipid binding domain as it forms an 
amphiphilic α-helix (AH) [8-10]. The addition of Nt17 shifts the aggregation process of 
polyQ in free solution to a pathway that includes oligomeric intermediates [11-13]. 
Further studies suggest that surfaces, including lipid membranes, can further modulate 
the aggregation process, favoring the formation of amorphous accumulations of htt exon1 
and small oligomers [14, 15]. Targeting the Nt
17
 domain with other molecules is an 
effective way of altering htt aggregation [11, 16]. A polyproline (polyP) domain is 
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directly adjacent to the C-terminal side of the polyQ domain in htt. The polyP sequence 
also influences the aggregation kinetic, conformational, and structural properties of htt 
[17, 18]. The aggregation of htt on model lipid membranes is also modulated by the 
presence of the polyP domain [15]. 
 Upon subcellular fractionation of neuron-like clonal striatal cells, ~ 50% of 
endogenous htt partitions with membranes [19]. Association of htt with lipids is further 
supported by the accumulation of lipid species in htt aggregates in transgenic mouse 
models of HD [20, 21]. Beyond playing a role in targeting lipid membranes, Nt
17
 
functions in trafficking htt to the endoplasmic reticulum, mitochondria, Golgi, and 
various vesicles [22-24]. N-terminal fragments of htt are observed in membranes that 
have been isolated from brain [4]. An apparent correlation of polyQ length with insertion 
into lipid membranes, [14, 25] suggests that htt's interactions with lipids may play a role 
in HD. In this regard, htt has been shown to disrupt bilayer structure, altering the local 
mechanical properties of supported membranes [14, 26].  
 A variety of protein motifs play a critical role in sensing and targeting specific 
physical properties of membranes. In particular, membrane curvature is a physical 
property targeted by amphipathic helices (AH) [27-29]. As the Nt
17
 domain of htt has 
been shown to have an amphipathic helical structure as a monomer, [30] fibril, [12] and 
when bound to lipids,[9, 10, 12] this study sought to determine if htt preferentially binds 
to curved membranes. In recent years, supported lipid bilayers have been increasingly 
used as model substrates for AFM studies aimed at understanding protein aggregation on 
membranes; [26, 31-36] however, as these supported bilayers are typically flat, it is 
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difficult to account for the potential role of membrane curvature in protein/lipid 
interaction using this method. In chapter 2, a system of a model supported lipid bilayers 
with both flat and curved regions were developed and validated. This system is exposed 
to a model htt peptide to determine if curvature plays a role in the interaction of htt with 
lipid membranes. The model, synthetic htt peptide was chosen based on several 
considerations: 1) 35 Gln repeats in synthetic peptides is sufficient for aggregation;[13] 
2) the polyP domain length (10 prolines) is similar to that directly adjacent to polyQ in htt 
exon1; 3) the known lipid-binding properties of Nt
17
;[22] and 4) this peptide has been 
demonstrated to effect lipid membranes in a similar manner to full htt exon1 proteins 
[15]. 
3.2 Materials and Methods 
3.2.1 In situ AFM imaging conditions 
 In situ AFM experiments were performed with a Nanoscope V MultiMode 
scanning probe microscope (Veeco, Santa Barbara, CA) equipped with a with a tapping 
mode fluid cell , an O ring, and a closed-loop vertical engage J-scanner. Images were 
taken with rectangular shaped silicon nitride cantilevers (Vista probes) with a nominal 
spring constant of 0.1 N/m (Phoenix, AZ). Typical scan rates ranged from 1-2 Hz, and 
drive frequencies of 5 - 6 kHz were used.  
 
3.2.2 Peptide Preparation 
 A synthetic peptide based on Htt exon1, Nt17Q35P10KK, was obtained via custom 
synthesis (Keck Biotechnology Resource Laboratory, New Haven, CT). Disaggregation 
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and solubilization of the peptides was achieved based on established protocols.[37] 
Briefly, crude peptide was dissolved for 3 h in a 1:1 mixture of trifluoroacetic acid (Acros 
Organics) and hexafluoroisopropanol (Acros Organics) at a concentration of 0.5 mg/ml. 
Samples were rigorously vortexed, and the solvent was then evaporated off with a gentle 
stream of N2. To remove any trace amounts of solvent from the peptide, samples were 
placed in a Vacufuge concentrator (Eppendorf). This process produced thin peptide films 
that were resuspended in ultrapure water adjusted to pH 3 with trifluoroacetic acid to 200 
μM, snap frozen, and stored at −80 °C. These stock solutions were thawed and 
immediately diluted with 10 mM Tris HCl buffer to a final concentration of 20 μM and 
with a resulting pH of 7.3. The peptides were injected directly into a fluid cell above a 
clean silicon substrate decorated with 50 nm silica beads. The surface was continually 
imaged once the peptide was injected.  
 
3.3 Results  
3.3.1 Htt peptides preferentially bind to curved bilayers.  
 In chapter 2, it was established that lipid bilayers covered both the curved and flat 
regions of the substrate. Here, these supported bilayers with both curved and flat regions 
were exposed to a synthetic truncated htt exon1 peptide (Nt
17
Q35P10KK) (Fig. 1). This 
peptide contained a 35 residue long polyQ domain flanked by the lipid binding Nt
17
 
domain and a 10 residue long polyP domain. Two lysines were added at the C-terminus 
of the peptide to aid in solubility [37]. Observations were limited to regions of the bilayer 
that were confirmed to be completely covered by lipid bilayer as determined by AFM 
analysis, prior to exposure to Nt
17
Q35P10KK. Addition of Nt
17
Q35P10KK indicated our  
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zero time-point for exposure, and no additional protein was added after this initial 
injection. For each experiment, Nt
17
Q35P10KK was freshly prepared and was in a 
predominately monomeric state upon initial injection; although, some small aggregates 
most likely were present. Control experiments exposing TBLE bilayers to protein-free 
vehicle solvents were performed, and no observable morphological changes in the bilayer 
were associated with injection of vehicle as assessed by AFM. The binding and 
aggregation of Nt
17
Q35P10KK on the bilayer surface was tracked by AFM imaging for 120 
 
Figure 1. Time lapse AFM images taken in solution of a TBLE bilayer exposed to a 
synthetic htt exon1 mimicking peptide ( Nt
17
Q35P10KK). Images were taken of the 
surface (a) before exposure  Nt
17
Q35P10KK and (b-d) at 30 minute increments after 
injection of the peptide.  
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minutes (Fig. 1). The portions of the surface occupied by beads visibly swelled within 30 
minutes of exposure to Nt
17
Q35P10KK as peptide accumulated on the curved bilayers and 
these curved regions continued to expand in volume with time. The increase in volume 
associated with the curved regions of the substrate occurred uniformly, as all curved 
regions appeared to be accumulating peptide. The accumulation of peptide by the curved 
bilayers predominately occurred in the lateral dimension, as an increase in the width of 
the regions associated with beads grew more quickly in comparison with the height (see 
example cross sections as a function of time in Fig.6e). The flat regions of the bilayer 
exhibited morphological changes i.e. became rougher, in discrete regions within the first 
30 minutes of exposure; however, unperturbed regions of the bilayer were still observed. 
With time, the area of the perturbed regions on the flat bilayers expanded and the 
roughness increased, this is indicative of htt binding, aggregating, and disrupting the 
bilayer. The height scale of the images presented in Fig.1 was optimized to demonstrate 
the binding of Nt
17
Q35P10KK to the curved bilayers. While a hint of the bilayer 
roughening can be observed in these images, adjusting the colormap demonstrates this 
more clearly (Fig. 2). A freshly formed bilayer on the flat portion of the substrate has a 
smooth appearance with an RMS roughness typically less than 0.2 nm. Exposure to 
Nt
17
Q35P10KK resulted in patches of increased surface roughness on the flat lipid bilayer, 
consistent with disruption of the bilayer structure by binding of the peptide. The RMS 
roughness of these regions exceeds 0.5 nm, and the roughness increases with time as 
more peptide binds and/or aggregates in these regions. 
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To quantify and compare the total amount 
of Nt
17
Q35P10KK that had bound to the 
curved and the flat regions of the bilayer 
respectively, the total volume change of the 
different regions was determined by AFM 
image analysis. As the flat regions of the 
bilayer represented a significantly larger 
surface area of the substrate, the change in 
volume was normalized per unit area. The 
initial volume of each lipid covered bead 
before exposure to Nt
17
Q35P10 ( 𝑉0 ) was 
subtracted for each subsequent 
measurements (Vt) to determine the volume 
change (ΔV) associated with deposition of 
peptide on curved bilayers at any given 
time. However, there are contributions to 
the measured volume of objects measured 
by AFM due to the finite size and shape of 
the probe tip, often referred to as tip 
convolution. This results in the measured volume of any given object in an AFM image 
being larger than the true volume of that object. Matlab based simulations of tip 
convolution [38] associated with AFM imaging of model beads that systematically 
increased in volume were performed to determine the expected error associated with the 
 Figure 2. (a) AFM image with adjusted 
height contrast shows that a synthetic htt 
exon1 mimicking peptide (Nt
17
Q35P10KK) 
aggregates on and disrupts the flat regions 
of the lipid bilayer. This image was taken 
90 minutes after the initial exposure to the 
Htt peptide. The regions indicated by blue 
perimeters have increased surface 
roughness associated with the binding and 
aggregation of Nt
17
Q35P10KK. The green 
line in the image corresponds to the height 
profile in (b). 
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finite size and shape of the tip in determining the volume of deposited peptide. On this 
model, the volume change (ΔV) associated with deposition of peptide on curved bilayers 
at any given time point was determined by: 
  
𝛥𝑉 = 𝑉0 − 𝑉𝑡        (1) 
 
A model 50 nm bead (approximated as a sphere, original object) was immobilized on a 
3D surface (Fig. 3a). The volume of this bead was systematically increased (expanded 
objects) to simulate the accumulation of peptide on a curved membrane supported by a 
bead. This was done in such a way that most of the volume was added in the lateral 
dimension as opposed to the vertical, which is similar to what was observed when 
exposing curved bilayers to peptide in experiment (Fig. 1e). As the exact volume of these 
model objects is known, the % increase in the true volume of the feature can be 
determined (table 1): 
 
Figure 3. Three dimensional renderings of model objects with increasingly larger 
volume are presented. (a) The true shape of the object (b) and the corresponding 
convoluted shape of the object after imaging with a tip of radius 15 nm 
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Increase in true volume =(
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑒𝑥𝑝𝑎𝑛𝑑𝑒𝑑 𝑜𝑏𝑗𝑒𝑐𝑡−𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑜𝑏𝑗𝑒𝑐𝑡
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑜𝑏𝑗𝑒𝑐𝑡
) ∗ 100 
          (2) 
 
Model AFM tips were constructed as hemispheres with varying radii. Results presented 
here are for a 15 nm tip. These tips were used to virtually image the model surfaces to 
obtain simulated AFM images with tip convolution (Fig. 8b). The % contribution due to 
tip convolution for each model object was calculated as: 
Table 1 
% increase in true 
volume 
% contribution due to 
convolution 
% error in measured 
volume change 
0.0 43.1 0.0 
6.0 40.4 -3.4 
11.4 39.3 2.6 
15.9 38.9 7.7 
21.9 37.0 9.5 
44.5 33.7 12.6 
70.1 30.0 11.4 
97.2 27.4 11.3 
126.8 24.9 10.6 
208.3 20.7 10.0 
302.0 17.8 9.4 
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% contribution due to tip convolution=
𝑉𝑡−𝑉𝑡𝑟𝑢𝑒
𝑉𝑡𝑟𝑢𝑒
× 100.  (3) 
where Vt is the measured volume after tip convolution and Vtrue is the true volume of the 
model object. Using equation 1, the true volume change and the measured volume change 
after tip convolution associated with our model objects was determined. The % error in 




× 100  (4) 
where ΔVwith convolution is the change in volume measured after tip convolution and ΔVtrue is 
the true change in volume. In short, these simulations indicated that while tip convolution 
caused the measured volume to typically be overestimated, this error never exceeded 
15%. The increased volume associated with flat regions of the bilayer was measured by 
summing up the volume of features observed above the baseline of the unperturbed 
bilayer height. By both of these measurements, the volume associated with the initial 
deposition of bilayer was controlled for both the curved and flat regions of the surface. 
Based on this analysis, Nt
17
Q35P10KK preferentially accumulated on the curved rather 
than the flat regions of the bilayer, even when taking into account the potential 15% 
overestimation due to tip convolution of the beads (Fig. 4).  Furthermore, shading has 
been added to Fig. 4 to indicate what the volume change associated with peptide 
deposition would be if there was a 15% overestimation, and this value was still 
significantly larger when compared to the amount of peptide deposited on flat regions of 
the bilayer. While Nt
17
Q35P10KK accumulated on both types of surfaces, significant  
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differences (p < 0.05) in the volume of deposited peptide were observed within 30 
minutes. The amount of deposited peptide increased linearly for the next hour for both 
regions of the bilayer; however, the accumulation of peptide occurred more rapidly on the 
curved regions. After ~90 minutes, accumulation of peptide on the curved bilayer 




Figure 4. Volume of deposited synthetic Htt exon1−mimicking peptide( 
Nt
17
Q35P10KK) on the curved or flat regions of the bilayer. The shaded region 
represents the estimated volume of peptide deposited on the curved bilayers after taking 
into account tip convolution (percent error assumed to be ≤15% based on simulations 
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3.4 Discussion 
 While tapping mode AFM in solution is widely used to study morphological and 
mechanical properties of supported lipid bilayers, one of the limitations associated with 
comparing these results to physiologically relevant membranes is the lack of membrane 
curvature associated with such systems. A potential method to induce curvature in 
supported lipid membranes is introducing local curvature in the substrate through 
depositing silica nanobeads onto a silicon substrate, and by the process of vesicle fusion, 
as discussed in detail in chapter 2. 
 When exposing these model bilayers to freshly prepared solutions of an N-
terminal htt fragment, it was found that the peptide preferentially accumulated on curved 
regions of the bilayer. While htt fragments with expanded polyQ domains are 
predominately found in nuclear or cytoplasmic inclusion bodies, [7] htt also directly 
associates with numerous membranous surfaces, such as mitochondria, endoplasmic 
reticulum, tubulovesicles, endosomes, lysosomes and synaptic vesicles, within the cell [2, 
39]. The environments provided by these membrane surfaces could influence the 
aggregation of htt with expanded polyQ domains, and these membranous structures 
exhibit varying degrees of curvature. This curvature may provide nucleation sites for 
aggregation by creating local areas of high htt concentration due to enhanced binding. 
The accumulation of monomeric htt and/or pre-fibrillar aggregates directly binding lipid 
membranes has been shown to disrupt bilayer integrity and induce mechanical changes in 
the membrane [14, 15, 26].  
 Beyond these implications of htt/lipid interactions in disease mechanisms, there 
are several membrane-associated functions attributable to htt in which the lipid binding 
  




 may play a role. Some of these functions include htt functioning in 
cellular adhesion, [40] motility, [41, 42] cholesterol and energy homeostasis, [43] as a 
molecular scaffold for coordination of membrane and cytoskeletal communication, [8] 
and facilitating micrutobule-dependent vesicle transport [44]. Nt
17
 facilitates the 
trafficking of htt exon1 to membranes associated with the ER, autophagic vacuoles, 
mitochondria, and Golgi [22, 23]. Membrane curvature sensing by the Nt
17
 domain of htt 
may represent a mechanistic detail of some of these functions, and disruption of these 
normal lipid associated functions of htt may play a role in toxicity associated with 
expanded polyQ domains. Supporting the notion that Nt
17
 directly interacts with lipid 
membranes, the binding of htt exon1 to large unilamellar vesicles comprised of PC or a 
mixture of PC and PS alters the helical content of the Nt
17
, and the associated changes in 
helical content could be inhibited by an addition of a proline at the 8
th
 residue of Nt
17
 
[22]. Structural studies utilizing solid state NMR suggest that Nt
17
 has a predominantly 
random coil structure in solution and adopts its α-helical structure upon binding lipid 
bilayers [9, 10]. Furthermore, the presence of Nt
17
 in synthetic polyQ peptides was 
necessary to bind model TBLE membranes and induce leakage of TBLE vesicles [15].  
 One potential mechanism to explain how Nt
17
, which is an AH, preferentially 
binds curved membranes is that bilayer curvature introduces a high density of membrane 
defects that can act as binding sites. AHs represent a common motif in a variety of 
proteins to sense membrane curvature [27-29]. The insertion process of AHs may be 
facilitated by lipid packing defects induced by the membrane curvature, resulting in a 
higher affinity of the protein for positively curved membranes [28, 45, 46]. However, 
recent studies have suggested that the curvature-selective binding of some AHs is due to 
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intrinsic properties of the membrane, that is, a higher density of binding sites rather than 
a higher affinity of the protein for the membrane [29]. Assuming that the lipid mass is 
conserved on both leaflets of a lipid bilayer and that the lipid composition of the bilayer 
remains constant, the density of defects within the leaflet of a bilayer associated with 
positive curvature would increase with bending [29]. Once a htt monomer (or possibly 
small aggregate) binds to the lipid membrane, this creates a site where more htt could 
preferentially accumulate through interaction with the immobilized bound peptide. This 
notion is supported by previous observations that monomeric htt exon1 proteins 
preferentially accumulate onto immobilized pre-formed aggregates, [47] and that htt 
exon1 tends to alter the morphology of lipid bilayers in discrete regions that grow in size 
with time [14, 15]. These discrete regions of disruption on the flat portions of the bilayer 
were also observed in this study. The binding of amyloid-forming proteins to membrane 
defects via AHs has been demonstrated for other amyloid-forming proteins, such as α-
synuclein [46, 48] and islet amyloid polypeptide [49].  
 While the data presented here suggests that the presence of bilayer defects 
induced by curvature can enhance the initial binding and accumulation of htt on 
membranes, several other factors can potentially play a role in regulating the interaction 
of htt exon1 fragments facilitated by Nt
17
 with lipid membranes. For example, several 
residues in Nt
17
 can undergo post translational modifications, such as phosphorylation, 
acetylation, and SUMOlyation, and some of these modifications have been shown to 
regulate the interaction of htt with specific organelles [22, 50]. Additional affinity-based 
components to the interaction of other AHs with lipid bilayers have been experimentally 
observed. Such considerations include electrostatics, [51, 52] partitioning of lipid 
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components,[53-55] or the presence of other specific recognition motifs [56, 57]. In 
particular, electrostatic mechanisms likely play a role in htt/lipid interactions, as htt binds 
multivalent phosphatidylinsoitol phospates (PIPs) and has a high affinity for cardiolipin 
[25, 58]. 
 
3.5 Conclusion  
 Apart from the lipid membrane curvature, it has become increasingly evident that 
there are several that determine the propensity of polyQ proteins to aggregate. Various 
factors, including posttranslational modifications may impact polyQ-aggregation process 
and its subsequent toxicity. Specifically, htt undergoes a variety of posttranslational 
modifications [59]. Acetylation and phosphorylation of threonine-3 are the most 
prevalent modifications of htt exon 1, which greatly impacts the aggregation of htt in 
cells and in vivo [60]. With AFM as robust imaging tool, detailed insights on the kinetics 
of posttranslational modifications on htt exon1 aggregation and the morphological 
characteristics of the resulting aggregates can be obtained. The impact of acetylation 
modification on htt aggregation is the focus of the next chapter. 
 
3.6 References 
1. Group, T.H.S.D.C.R., A novel gene containing a trinucleotide repeat that is 
expanded and unstable on Huntington's disease chromosomes. Cell, 1993. 72(6): 
p. 971-983. 
  
  91 
 
2. DiFiglia, M., et al., Aggregation of huntingtin in neuronal intranuclear inclusions 
and dystrophic neurites in brain. Science, 1997. 277(5334): p. 1990-1993. 
3. Ravina, B., et al., The relationship between CAG repeat length and clinical 
progression in Huntington's disease. Movement Disorders, 2008. 23(9): p. 1223-
1227. 
4. Kim, Y.J., et al., Caspase 3-cleaved N-terminal fragments of wild-type and 
mutant huntingtin are present in normal and Huntington's disease brains, 
associate with membranes, and undergo calpain-dependent proteolysis. 
Proceedings of the National Academy of Sciences of the United States of 
America, 2001. 98(22): p. 12784-12789. 
5. Ratovitski, T., et al., Mutant Huntingtin N-terminal Fragments of Specific Size 
Mediate Aggregation and Toxicity in Neuronal Cells. Journal of Biological 
Chemistry, 2009. 284(16): p. 10855-10867. 
6. Ratovitski, T., et al., N-terminal proteolysis of full-length mutant huntingtin in an 
inducible PC12 cell model of Huntington's disease. Cell Cycle, 2007. 6(23): p. 
2970-2981. 
7. Davies, S.W., et al., Formation of neuronal intranuclear inclusions underlies the 
neurological dysfunction in mice transgenic for the HD mutation. Cell, 1997. 
90(3): p. 537-548. 
8. Kegel, K.B., et al., Huntingtin associates with acidic phospholipids at the plasma 
membrane. Journal of Biological Chemistry, 2005. 280(43): p. 36464-36473. 
  
  92 
 
9. Michalek, M., E.S. Salnikov, and B. Bechinger, Structure and Topology of the 
Huntingtin 1-17 Membrane Anchor by a Combined Solution and Solid-State NMR 
Approach. Biophysical Journal, 2013. 105(3): p. 699-710. 
10. Michalek, M., et al., Membrane Interactions of the Amphipathic Amino Terminus 
of Huntingtin. Biochemistry, 2013. 52(5): p. 847-858. 
11. Jayaraman, M., et al., Slow Amyloid Nucleation via alpha-Helix-Rich Oligomeric 
Intermediates in Short Polyglutamine-Containing Huntingtin Fragments. Journal 
of Molecular Biology, 2012. 415(5): p. 881-899. 
12. Sivanandam, V.N., et al., The Aggregation-Enhancing Huntingtin N-Terminus Is 
Helical in Amyloid Fibrils. Journal of the American Chemical Society, 2011. 
133(12): p. 4558-4566. 
13. Thakur, A.K., et al., Polyglutamine disruption of the huntingtin exon 1 N terminus 
triggers a complex aggregation mechanism. Nature Structural & Molecular 
Biology, 2009. 16(4): p. 380-389. 
14. Burke, K.A., et al., Huntingtin disrupts lipid bilayers in a polyQ-length dependent 
manner. Biochimica Et Biophysica Acta-Biomembranes, 2013. 1828(8): p. 1953-
1961. 
15. Burke, K.A., et al., The Interaction of Polyglutamine Peptides with Lipid 
Membranes Is Regulated by Flanking Sequences Associated with Huntingtin. 
Journal of Biological Chemistry, 2013. 288(21): p. 14993-15005. 
16. Mishra, R., et al., Inhibiting the Nucleation of Amyloid Structure in a Huntingtin 
Fragment by Targeting alpha-Helix-Rich Oligomeric Intermediates. Journal of 
Molecular Biology, 2012. 415(5): p. 900-917. 
  
  93 
 
17. Bhattacharyya, A., et al., Oligoproline effects on polyglutamine conformation and 
aggregation. Journal of Molecular Biology, 2006. 355(3): p. 524-535. 
18. Darnell, G., et al., Flanking polyproline sequences inhibit beta-sheet structure in 
polyglutamine segments by inducing PPII-like helix structure. Journal of 
Molecular Biology, 2007. 374(3): p. 688-704. 
19. Kegel, K.B., et al., Huntingtin expression stimulates endosomal-lysosomal 
activity, endosome tubulation, and autophagy. Journal of Neuroscience, 2000. 
20(19): p. 7268-7278. 
20. Suopanki, J., et al., Interaction of huntingtin fragments with brain membranes - 
clues to early dysfunction in Huntington's disease. Journal of Neurochemistry, 
2006. 96(3): p. 870-884. 
21. Valencia, A., et al., Mutant Huntingtin and Glycogen Synthase Kinase 3-beta 
Accumulate in Neuronal Lipid Rafts of a Presymptomatic Knock-In Mouse Model 
of Huntington's Disease. Journal of Neuroscience Research, 2010. 88(1): p. 179-
190. 
22. Atwal, R.S., et al., Huntingtin has a membrane association signal that can 
modulate huntingtin aggregation, nuclear entry and toxicity. Human Molecular 
Genetics, 2007. 16(21): p. 2600-2615. 
23. Rockabrand, E., et al., The first 17 amino acids of Huntingtin modulate its sub-
cellular localization, aggregation and effects on calcium homeostasis. Human 
Molecular Genetics, 2007. 16(1): p. 61-77. 
  
  94 
 
24. Trettel, F., et al., Dominant phenotypes produced by the HD mutation in 
STHdh(Q111) striatal cells. Human Molecular Genetics, 2000. 9(19): p. 2799-
2809. 
25. Kegel, K.B., et al., Polyglutamine expansion in huntingtin increases its insertion 
into lipid bilayers. Biochemical and Biophysical Research Communications, 
2009. 387(3): p. 472-475. 
26. Burke, K.A., E.A. Yates, and J. Legleiter, Amyloid-Forming Proteins Alter the 
Local Mechanical Properties of Lipid Membranes. Biochemistry, 2013. 52(5): p. 
808-817. 
27. Drin, G. and B. Antonny, Amphipathic helices and membrane curvature. FEBS 
Letters, 2010. 584(9): p. 1840-1847. 
28. Drin, G., et al., A general amphipathic alpha-helical motif for sensing membrane 
curvature. Nature Structural & Molecular Biology, 2007. 14(2): p. 138-146. 
29. Hatzakis, N.S., et al., How curved membranes recruit amphipathic helices and 
protein anchoring motifs. Nature Chemical Biology, 2009. 5(11): p. 835-841. 
30. Kim, M.W., et al., Secondary Structure of Huntingtin Amino-Terminal Region. 
Structure, 2009. 17(9): p. 1205-1212. 
31. Drolle, E., Ravi M. Gaikwad, and Z. Leonenko, Nanoscale Electrostatic Domains 
in Cholesterol-Laden Lipid Membranes Create a Target for Amyloid Binding. 
Biophysical Journal, 2012. 103(4): p. L27-L29. 
32. Hane, F., E. Drolle, and Z. Leonenko, Effect of cholesterol and amyloid-β peptide 
on structure and function of mixed-lipid films and pulmonary surfactant BLES: an 
  
  95 
 
atomic force microscopy study. Nanomedicine: Nanotechnology, Biology and 
Medicine, 2010. 6(6): p. 808-814. 
33. Legleiter, J., et al., The Modulating Effect of Mechanical Changes in Lipid 
Bilayers Caused by ApoE-Containing Lipoproteins on A beta Induced Membrane 
Disruption. Acs Chemical Neuroscience, 2011. 2(10): p. 588-599. 
34. Yates, E.A., et al., Specific Domains of A beta Facilitate Aggregation on and 
Association with Lipid Bilayers. Journal of Molecular Biology, 2013. 425(11): p. 
1915-1933. 
35. Yip, C.M., A.A. Darabie, and J. McLaurin, A beta 42-peptide assembly on lipid 
Bilayers. Journal of Molecular Biology, 2002. 318(1): p. 97-107. 
36. Yip, C.M., et al., Cholesterol, a modulator of membrane-associated A beta-
fibrillogenesis and neurotoxicity. Journal of Molecular Biology, 2001. 311(4): p. 
723-734. 
37. Chen, S.M. and R. Wetzel, Solubilization and disaggregation of polyglutamine 
peptides. Protein Science, 2001. 10(4): p. 887-891. 
38. Villarrubia, J.S., Algorithms for scanned probe microscope image simulation, 
surface reconstruction, and tip estimation. Journal of Research of the National 
Institute of Standards and Technology, 1997. 102(4): p. 425-454. 
39. Gutekunst, C.A., et al., Nuclear and neuropil aggregates in Huntington's disease: 
relationship to neuropathology. J Neurosci, 1999. 19(7): p. 2522-34. 
40. Strehlow, A.N., J.Z. Li, and R.M. Myers, Wild-type huntingtin participates in 
protein trafficking between the Golgi and the extracellular space. Hum Mol 
Genet, 2007. 16(4): p. 391-409. 
  
  96 
 
41. Ritch, J.J., et al., Multiple phenotypes in Huntington disease mouse neural stem 
cells. Molecular and Cellular Neuroscience, 2012. 50(1): p. 70-81. 
42. Myre, M.A., et al., Deficiency of huntingtin has pleiotropic effects in the social 
amoeba Dictyostelium discoideum. PLoS Genet, 2011. 7(4): p. e1002052. 
43. Jacobsen, J.C., et al., HD CAG-correlated gene expression changes support a 
simple dominant gain of function. Hum Mol Genet, 2011. 20(14): p. 2846-60. 
44. Caviston, J.P. and E.L. Holzbaur, Huntingtin as an essential integrator of 
intracellular vesicular trafficking. Trends Cell Biol, 2009. 19(4): p. 147-55. 
45. Cornell, R.B. and S.G. Taneva, Amphipathic helices as mediators of the 
membrane interaction of amphitropic proteins, and as modulators of bilayer 
physical properties. Current Protein & Peptide Science, 2006. 7(6): p. 539-552. 
46. Nuscher, B., et al., alpha-synuclein has a high affinity for packing defects in a 
bilayer membrane - A thermodynamics study. Journal of Biological Chemistry, 
2004. 279(21): p. 21966-21975. 
47. Legleiter, J., et al., Mutant Huntingtin Fragments Form Oligomers in a 
Polyglutamine Length-dependent Manner in Vitro and in Vivo. Journal of 
Biological Chemistry, 2010. 285(19): p. 14777-14790. 
48. Davidson, W.S., et al., Stabilization of alpha-synuclein secondary structure upon 
binding to synthetic membranes. Journal of Biological Chemistry, 1998. 273(16): 
p. 9443-9449. 
49. Caillon, L., O. Lequin, and L. Khemtemourian, Evaluation of membrane models 
and their composition for islet amyloid polypeptide-membrane aggregation. 
Biochimica Et Biophysica Acta-Biomembranes, 2013. 1828(9): p. 2091-2098. 
  
  97 
 
50. Xia, J.R., et al., Huntingtin contains a highly conserved nuclear export signal. 
Human Molecular Genetics, 2003. 12(12): p. 1393-1403. 
51. McLaughlin, S. and D. Murray, Plasma membrane phosphoinositide organization 
by protein electrostatics. Nature, 2005. 438(7068): p. 605-611. 
52. Yeung, T., et al., Membrane phosphatidylserine regulates surface charge and 
protein localization. Science, 2008. 319(5860): p. 210-213. 
53. Linder, M.E. and R.J. Deschenes, Palmitoylation: policing protein stability and 
traffic. Nature Reviews Molecular Cell Biology, 2007. 8(1): p. 74-84. 
54. Manneville, J.-B., et al., COPI coat assembly occurs on liquid-disordered 
domains and the associated membrane deformations are limited by membrane 
tension. Proceedings of the National Academy of Sciences of the United States of 
America, 2008. 105(44): p. 16946-16951. 
55. Rocks, O., et al., An acylation cycle regulates localization and activity of 
palmitoylated Ras isoforms. Science, 2005. 307(5716): p. 1746-1752. 
56. Lemmon, M.A., Membrane recognition by phospholipid-binding domains. Nature 
Reviews Molecular Cell Biology, 2008. 9(2): p. 99-111. 
57. McMahon, H.T. and J.L. Gallop, Membrane curvature and mechanisms of 
dynamic cell membrane remodelling. Nature, 2005. 438(7068): p. 590-596. 
58. Kegel-Gleason, K.B., Huntingtin Interactions with Membrane Phospholipids: 
Strategic Targets for Therapeutic Intervention? Journal of Huntington's Disease, 
2013. 2(3): p. 239-250. 
59. Hands, S.L. and A. Wyttenbach, Neurotoxic protein oligomerisation associated 
with polyglutamine diseases. Acta Neuropathologica, 2010. 120(4): p. 419-437. 
  
  98 
 
60. Aiken, C.T., et al., Phosphorylation of Threonine 3 Implications for huntingtin 





4. Acetylation alters huntingtin aggregation and membranes 
 
4. Acetylation within the first 17 amino acids of huntingtin exon1 alters     




 Huntington disease (HD) is a genetic neurodegenerative disorder caused by an 
expanded polyglutamine (polyQ) domain near the N-terminus of the huntingtin (htt) 
protein. Expanded polyQ directly leads to htt aggregation. The first 17 amino acids (Nt
17
) 
in htt is a lipid-binding domain that also promotes diverse aggregate species of htt. Nt
17
 
undergoes a number of posttranslational modifications that can modulate htt’s toxicity, 
subcellular localization, and trafficking of vesicles. N-terminal acetylation of htt has been 
implicated in the etiology of HD. Given the importance of acetylation in HD, this study 
sought to evaluate the impact of lysine acetylation on htt aggregation in solution and on 
model lipid bilayers. Acetylation of htt-exon1(51Q), and synthetic truncated htt exon1 
mimicing peptides (Nt
17
Q35P10KK) was achieved using a selective covalent label sulfo-N-
hydroxysuccinimide (NHSA) in molar ratios of 1x, 2x, and 3x NHSA per peptide. With 
this treatment, all three lysine residues (K6, K9, and K15) in Nt
17
 were significantly 
labeled. N-terminal htt acetylation decreased fibril formation in solution and promoted 
the formation of larger globular aggregates. Acetylation strongly altered htt’s ability to 
bind lipid membranes. Acetylated htt bound lipid membranes and disrupted lipid bilayer 
morphology less aggressively compared to unlabeled htt. Mechanistic insights into how 
acetylation alters the interaction of Nt
17 
with lipid membranes were provided by 
computational studies. The results presented here, highlight that N-terminal acetylation 
influences the aggregation of htt and its interaction with lipid bilayers. 
                                                          
1
 This chapter is based on submitted manuscript “Acetylation alters huntingtin aggregation and 
membranes” 
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4.1 Introduction: Huntingtin’s disease and post translational modifications. 
 Huntington’s disease (HD) is a neurodegenerative disorder caused by an 
expanded CAG trinucleotide repeat in the IT15 gene that codes for the huntingtin (htt) 
protein. This CAG expansion encodes an abnormal stretch of more than 35-40 
polyglutamine (polyQ) repeats within the first exon of htt [1]. In HD, the age of onset and 
severity in disease is highly correlated with polyQ length [2, 3]. Expanded polyQ 
domains in htt are directly implicated in the aggregation of htt into fibrils and a variety of 
other structures [4-6]. The polyQ domain is located in the first exon of htt, beginning 
with the 18
th
 residue, and substantial evidence points to N-terminal fragments of htt 
comparable to exon 1 being involved in HD [7-12].  
In HD patients’ brains, mutant htt is detected predominantly in microscopic 
inclusion bodies in the cytoplasm and nucleus [10], but it also associates with 
membranous organelles, including mitochondria, endoplasmic reticulum (ER), 
tubulovesicles, endosomes, lysosomes and synaptic vesicles [13-16]. Approximately half 
of endogenous htt partitions with membranes after subcellular fractionation of neuron-
like clonal striatal cells [17]. Futhermore, membraneous structures are assimilated onto 
the surfaces of htt inclusion bodies in cellular models [17, 18], and htt aggregates 
accumulate brain lipids in mouse models of HD [19, 20]. With regards to N-terminal 
fragments of htt, Nt
17
 is required for membrane localization [21, 22] and regulates lipid 
binding [23]. Beyond functioning in lipid binding, Nt
17 
promotes oligomer formation [24, 
25], and targeting Nt
17 
directly is an effective strategy for inhibiting aggregation [24, 26]. 
In solution, monomeric Nt
17 
is predominately disordered, as demonstrated by 
NMR [25], but circular dichroism (CD) studies suggest that Nt
17
 contains 10–50% α-
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helical content, depending on buffer conditions [21, 25, 27, 28]. This suggests that Nt
17 
may adopt multiple configurations. Such a notion is supported by computational studies, 
some of which predict that Nt
17 can form an α-helix in aqueous solution [29, 30]; others 
suggest that Nt
17 
is predominately unstructured in solution [28, 31-34]. However, the Nt
17 
domain appears to be α-helical in at least some aggregate forms of htt [26, 35, 36], and it 
transitions to an α-helical structure upon self-association [24] or when it interacts with 
phospholipids, detergents, or other apolar compounds [21, 25, 27, 37]. Furthermore, 
recent IMS-MS experiments suggest the presence of coexisting solution conformers for 
Nt
17
 peptides [38]. 
Several post translational modifications (PTMs) including proteolytic cleavage, 
acetylation, phosphorylation, ubiquitination, and SUMOylation, are associated with HD 
pathogenesis [39-41]. Dysregulation of PTMs triggered by expanded polyQ tracts may 
lead to aberrant htt interactions [42]. A number of PTM sites are located in the 
Nt
17
domain, with some sites associated with multiple modifications [43]. Specifically, 
proteomic mapping by mass spectrometry (MS) identified acetylation sites at K6, K9, and 
K15 [44]. This N-terminal acetylation preferentially occurred in htt with polyQ lengths 
below the disease threshold, suggesting that decreased acetylation of expanded htt could 
play a role in pathogenic mechanisms associated with HD.  
Membrane related changes are a clear biochemical feature of HD [45-47]. Htt 
predominately localizes to a variety of membranous surfaces within cells, and its strong 
association with lipids may play a prominent role in the normal function of htt [45, 48]. 
Amino-terminal mutant htt fragments have been shown to aggregate on and damage a 
variety of phospholipid bilayers, suggesting that phospholipid interactions may play a 
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role htt-related toxicity [19, 23, 49]. As a result, determining factors that regulate the 
affinity of htt for membranes is critical in understanding not only the normal functions of 
htt, but also in identifying ways to modify htt/lipid interactions for potential therapeutic 
strategies. It is clear that Nt
17 
influences the aggregation of N-terminal fragments of htt 
[24, 26, 35] and their direct interactions with lipid membranes [23, 27, 37, 50, 51]. 
Furthermore, PTMs within Nt
17
 have a profound effect not only on htt function and 
translocation [52-54], but also on the toxicity associated with mutant htt containing 
expanded polyQ domains [42, 43, 55-57]. However, the impact of acetylation of Nt
17 
on 
modulating htt aggregation and its interactions with lipid bilayers is poorly understood. 
The aim here is to elucidate the influence of acetylation of Nt
17 
on these phenomena. 
 
4.2 Materials and Methods 
4.2.1 Peptide preparation.  
 Synthetic Nt
17
Q35P10KK was purchased from the Keck institute (Yale University) 
and stored at −20 °C until later use. The synthetic, model htt peptide used in this study 
contains 35 glutamines (which is sufficient for aggregation), [58] a C-terminal 
polyproline (polyP) domain that is ten residues in length, and the previously mentioned 
Nt
17
 on the N-terminus. Disaggregation and solubilization of peptides were achieved by a 
variation on published protocols [59]. In short, 1.0-mg portions were dissolved in 1.00 ml 
of 50/50 trifluoroacetic acid/hexafluoroisopropanol (TFA/HFIP) to ensure 
disaggregation. The samples were aliquoted into 250-µl portions and dried under a steady 
stream of nitrogen until most of the TFA/HFIP was removed. The aliquots were then 
placed in a centrifugal evaporator for 3 h to ensure removal of all TFA/HFIP. The 
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resulting 0.250-mg peptide films were stored at −20 °C until further use. The peptide 
films were reconstituted in pH 3 TFA, and then diluted to 20 μM in pH 7 PBS. Labeling 
was performed immediately after reconstitution at the three molar ratios. The labeling 
reaction was quenched by the addition of 100 µL Tris HCl after a one-minute reaction 
time. 50 µL of acetonitrile was added to each sample to prevent aggregation before 
enzymatic digestion. 2.0 µL of 1.0 mg/mL chymotrypsin was added to each sample and 
allowed to digest overnight at 37°C. Digestion was quenched by addition of 5 µL of 
formic acid. Samples were aliquoted and immediately analyzed by LC-MS/MS. 
 
4.2.2 Liquid Chromatography/Tandem Mass Spectrometry.  
 LC-MS/MS was performed using an Accela binary pump LC coupled to a Q 
Exactive mass spectrometer (Thermo Scientific, San Jose, CA). Separation was 
facilitated using a Synergi Fusion RP-80 2.0 x 100 mm column, particle size of 4 micron 
(Phenomenex, Torrance, CA) with water 0.1% formic acid as solvent A, and acetonitrile 
with 0.1% formic acid as solvent B. A 60 minute gradient was used (5 – 100% B over 60 
minutes) with a ten minute column re-equilibration between successive runs, at a flow 
rate of 0.200 mL/min. A 20 µL sample injection was used for all injections. The mass 
spectrometer was operated in a data-dependent mode, where the 5 most intense ions in 
each scan were submitted for MS/MS HCD fragmentation. Data analysis was performed 
using Thermo Proteome Discoverer (Thermo Scientific). A database containing only the 
peptide of interest was generated manually and used as search criteria. The program 
searched for both acetylated and unmodified peptide ions of interest within each LC-
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MS/MS dataset. Peak areas for ions that contained the specific lysine residue were 
recorded for all labeled and unlabeled ions. Percent modification for each lysine residue 
was reported as a percent of the total ion signal for the residue in question: 
%𝑀𝑜𝑑 =  
∑ 𝑀𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝑖𝑜𝑛 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎
∑ 𝑀𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎+ ∑ 𝑈𝑛𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎
 (1) 
 
4.2.3 Thioflavin T (ThT) assay.  
 The assay was performed using a Molecular Devices M5 spectrophotometer 
(Molecular Devices, LLC, Sunnyvale, CA, USA). Stock ThT (Sigma Aldrich, St. Louis, 
MO, USA) was prepared in nanopure water at a concentration of 1.0 mg/ml. Peptide 
labeling with NHSA was performed immediately after reconstitution, and immediately 
before analysis. 2.0 µL of the stock ThT was spiked into the sample (100 µl total sample 
volume/well). Sample fluorescence was monitored using 440-nm excitation and 480-nm 
emission wavelengths. Samples were kept at 25 °C for the duration of the assay. 
Emission data points were acquired every minute for 6 h for each NHSA concentration. 
Background fluorescence was obtained from a blank sample that contained no peptide, 
collected simultaneously with the analyte. Each peptide sample was run in triplicate and 
averaged. The average background signal was subtracted from each data point in the 
spectrum to obtain the actual fluorescence associated with β-sheet formation. Signal was 
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4.2.4 Purification of Glutathione S-transferase (GST)-htt-exon1 fusion 
 proteins.  
 GST-htt exon1 51Q fusion proteins were purified as described elsewhere [20, 60]. 
In short, expression of GST-htt fusion proteins was induced in Escherichia coli by 
isopropyl β-D-thiogalactoside for 4h at 30oC. The cells were lysed with 0.5mg/ml of 
lysozyme. Liquid chromatography (LPLC, Bio-Rad) with a GST affinity column was 
used to purify the fusion proteins from the lysate. Relevant fractions to collect and purify 
were determined by gel electrophoresis, and purity of fusion proteins was consistently 
greater than 95%. Prior to all experiments, solutions with all GST-htt exon1 51Q fusion 
proteins were high spin centrifuged at 20000 x g for 30 min at 4
o
C to remove pre-existing 
aggregates. To initiate aggregation, the cleavage of the GST moiety was performed by 
the addition of Factor Xa protease (Promega, Madison, WI) for 1h in ice. Experiments 
were carried out in PBS buffer. 
 
4.2.5 Acetylation of htt exon1 51Q.  
 Htt was acetylated using selective covalent label, sulfo-N-hydroxysuccinimide 
acetate (NHSA) [61]. Stock solutions of NHSA were prepared in water to make 
1.71mg/ml solution. The labeling of htt was carried out in NHSA/htt molar ratios to 
achieve 1x, 2x and 3x NHSA labeling for 1 min, and the reaction was quenched by 
adding 10mM Tris. The labeling was confirmed by MS. After acetylation, factor Xa 
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4.2.6 Protein samples for ex situ AFM imaging.  
 The GST proteins (htt 51Q, + 1x NHSA, +2x NHSA, +3x NHSA) at 20 µM in 
Eppendorf tubes were incubated at 37oC and 1400 rpm for the duration of the experiment. 
At 0, 1, 3, 5, 8, 24 h after cleavage of GST with factor Xa protease, aliquots (5µl) from 
each incubation sample were spotted onto freshly cleaved mica (Ted Pella Inc., Redding, 
CA), for 30seconds, washed with 200µl of ultra-pure water and dried gently with a 
stream of air. There mica was placed on metal pucks and imaged with AFM. 
 
4.2.7 Preparation of lipid bilayers.  
 The lyophilized total brain lipid extract (TBLE) (Avanti Polar Lipids, Alabaster, 
AL) was reconstituted in 10mM PBS (pH 7.3) with vortexing to a concentration of 
1mg/ml. Using liquid nitrogen, the lipid sample went through five cycles of freeze-thaw 
to facilitate bilayer and multilayer lipid sheet formation [62]. The lipid samples were then 
sonicated for 20 min to facilitate vesicle formation. A 40µL aliquot of 0.5mg/ml TBLE 
was added into AFM fluid cell. A 25 µm x 25 µm lipid bilayer formed on the mica 
surface via vesicle fusion. The formation of the bilayer was monitored by continuous 
AFM imaging. Once fully formed, the bilayer was washed twice with 15µl of PBS to 
remove excess lipid vesicles. 
 
4.2.8 AFM imaging conditions.  
 All AFM experiments were performed with a Nanoscope V Multimode AFM 
(Veeco,Santa Barbara,CA) equipped with a closed loop vertical engage J-scanner. For ex 
situ AFM experiments, all images were acquired with diving board shaped silicon-oxide 
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cantilevers with a nominal spring constant of 40 N/m and resonance frequency around 
300 kHz. For in situ AFM experiments, a tapping mode fluid cell with an O ring was 
equipped with a rectangular shaped silicon nitride cantilevers (Vista probes) with a 
nominal spring constant of 0.1 N/m. The scan rates were set between 1-2 Hz at 512 pixels 
per line and drive frequencies of 5 - 6 kHz were used with the set point of 0.70. 
 
4.2.9 Imaging Processing.  
 All images were analyzed using Matlab with the image processing toolbox 
(MathWorks, Natick, MA) [63]. Physical dimensions of aggregates were measured 
automatically by (i) importing the images into Matlab, (ii) using a flattening algorithm to 
flatten the images to correct for background curvature, (iii) creating a binary map of the 
surface to locate individual aggregates using a height threshold, (iv) locating discrete 
aggregates by applying pattern recognition algorithms to the binary maps, and (v) finally 
the physical features (height, length etc) of individual aggregates were automatically 
measured . 
 
4.2.10 Preparation of TBLE/PDA vesicles.  
 The polydiacetylene (PDA) assay was prepared using protocols previously 
described [64-67]. Briefly, TBLE and diacetylene monomer 10, 12 tricosadiynoic acid 
(GFS Chemicals, Columbus, OH) in 2:3 molar ratio were mixed in 3 ml of solution of 
ethanol /chloroform (1:1) in a round bottomed flask. The solution was dried by rotavap 
leaving a thin dry film. This was followed by the addition of 14.8 ml of 1x Tris buffered 
saline (heated to 70
o
C), and sonicated on high for 5 min at 100 W using a sonic 
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dismembrator (FischerSci).The suspension was stored at 4
o
C overnight, then polymerized 
by irradiation with 7 lumens (UV analyzer) at 254nm for 10 min while stirring 
thoroughly at room temperature giving a blue TBLE/PDA chromatic solution. The 
solution was kept in a glass container, covered with foil prior to experiments. 
 
4.2.11 Preparation of PDA/htt sample solutions.  
 The assay included PDA +1x Tris (negative control), PDA+1x Tris +NaOH (pH 
12; positive control), and PDA mixed with each of the four sample solutions described 
previously (htt-exon1 (51Q), htt +1x NHSA, htt +2xNHSA, htt +3xNHSA). Each sample 
was loaded in a 96 well plate in triplicate to achieve a final protein concentration of 
20µM in each well. The kinetic absorbance measurements was recorded for 16 h on 
infinite M1000 Pro plate reader (TECAN, Switzerland) at 22
o
C with 3 sec shaking 
between reads .The plate reader was set to record both the blue (640 nm) and the red 
component (500 nm) of the spectrum for each sample. Colorimetric response (%CR) was 
used as a quantitative measurement of PDA/protein interaction. 
 
4.3 Results  
4.3.1 Chemically-induced acetylation occurs at all lysines in Nt
17 
and inhibits 
 aggregation.  
 In htt-exon1 there are three lysine residues available for acetylation that are 
located in Nt
17
 (K6, K9, and K15). To determine their availability for acetylation, model 
htt peptides were exposed to sulfo-N-hydroxysuccinimide acetate (NHSA), an established 
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agent for labeling primary amines in proteins [68, 69]. The model htt peptide contained 
the Nt
17
 domain, 35 repeat glutamines, a 10-residue polyproline domain, and two C-
terminal lysines (Nt
17
-Q35-P10-KK) to aid solubility. Nt
17
-Q35-P10-KK was used in place 
of the GST-fusion construct to reduce spectral complexity and eliminate ions that 
correspond to missed GST-htt cleavages. In cases where MS/MS data was insufficient or 
not available, the exact monoisotopic mass of a labeled ion was used for identification of 
an ion of interest. If this ion were produced from a peptide of a missed GST cleavage 
product, then this method would lead to a false-positive for a labeling event, skewing the 
results. As there are three lysines in Nt
17
, labeling was carried out in molar ratios of 1x, 
2x, and 3x NHSA to htt, with quenching of the labeling reaction after 1 min by addition 
of 10 mM Tris. Acetylated lysines were verified using chymotrypsin and MS to measure 
the relative amount of labeled and unlabeled fragments containing single lysine residues 
(Fig. 1a), and ThT assays were run to determine the impact of acetylation on Nt
17
-Q35-
P10-KK aggregation (Fig. 1b). Chymotrypsin was selected over other serine proteases 
(such as trypsin) as its enzymatic activity is unaffected by substitution of the lysine 
primary amine. Overall, K9 was the most readily labeled, followed by K6 and K15. At 1x 
NHSA, all three lysines in Nt
17
 were labeled to some extent, but no more than 30%. With 
2x NHSA, K9 was acetylated to a significantly larger extent (69%) than the other two 
lysines. At 3x NHSA, K9 acetylation increased to over 80%, and over 60% of K6 was 
labeled. Acetylation of K15 increased with larger doses of NHSA, but it was never over 
30% acetylated. The two flanking lysines at the C-terminus were not appreciably 
acetylated under any dose of NHSA. As acetylation increased, 
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aggregation was inhibited in a dose dependent manner. At 1xNHSA, there was a slightly 
slower rate of aggregation (Fig. 1). 2x NHSA increased the lag phase with an overall 
reduced rate of aggregation. At 3x NHSA, aggregation was significantly decreased. This 
inhibition of aggregation suggests that K6 and K9 may play important roles in 
aggregation as reduced aggregation was observed once these residues were appreciably 
labeled.  
 
4.3.2 Acetylation of Nt
17 
inhibits htt-exon1 fibril formation.  
 To determine the impact of acetylation on full length htt-exon1 aggregation, a 
mutant htt fragment, that expresses exon1 with 51Q (htt-exon1(51Q)), was exposed to 
different amounts of NHSA and the aggregation tracked. Htt-exon1(51Q) was purified 
from Escherichia coli as a soluble fusion with glutathione S-transferase (GST) [60]. The 
GST moiety was cleaved with a site-specific protease (Factor Xa), releasing the htt-
exon1(51Q) fragment and initiating aggregation [70]. Htt-exon1(51Q) was exposed to 
NHSA in molar ratios of 0:1, 1:1, 2:1, or 3:1 in a similar fashion as Nt
17
-Q35-P10-KK. To  
Figure 1. Lysines within Nt
17
 are accessible for acetylation and impact fibril 
formation. (a) MS analysis of the extent of lysine acetylation by NHSA in Nt
17
 for a 
model peptide Nt
17
-Q35-P10-KK. Error bars represent the standard deviation. (b) ThT 
aggregation assays demonstrating the impact of lysine acetylation by NHSA on Nt
17
-
Q35-P10-KK fibril formation. 
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verify that addition of the NHSA would not interfere with the removal of the GST tag, 
fusion protein that had been exposed to the different molar ratios of NHSA were 
incubated with Factor Xa on ice for one hour and analyzed using SDS-PAGE (Fig. 2). 
Densitometry analysis of the resulting gels demonstrated that there was no appreciable 
difference in the efficiency of cleaving the GST tag upon addition of NHSA. 
Incubation experiments were performed with freshly prepared 20 μM solutions of 
htt-exon1(51Q) that had been acetylated by NHSA at the different molar ratios. Aliquots 
were removed from the solutions after 1, 3, 5, 8 and 24 h of incubation for AFM analysis 
(Fig. 3). In an effort to quantify the effect of acetylation on htt aggregation, AFM images 
from all incubations were analyzed by counting the number of oligomers or fibrils per 
μm2 at each time point (Fig. 3b-c). For this analysis, aggregates were defined as objects in 
Figure 2. Addition of NHSA to GST-htt-exon1 (51Q) does not inhibit cleavage of 
the GST tag by Factor Xa. (a) SDS-PAGE demonstrating the efficiency of cleaving 
the GST tag of the fusion protein that had been acetylated with varying amounts of 
NHSA. (b) Densitometry analysis was used to determine the percent of cleaved htt-
exon1 (51Q) as a function of total protein in the presence of varying amounts of 
NHSA. 
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the image taller than 2 nm. Fibrils were distinguished from oligomers by a length-to-
width (aspect) ratio filter. Fibrils had an aspect ratio >3; oligomers had an aspect ratio < 3 
[63]. Htt-exon1(51Q) incubated without any NHSA quickly formed a variety of 
oligomers and fibrils (Fig. 3). The number of oligomers per unit area fluctuated from 15-
22 without any significant changes over 24 h. The number of fibrils, however, steadily 
increased over 24 h. At 1 h, only a small number of fibrils were present, and these 
increased in number and grew from several hundred nanometers to > 1 μm in length at 
later time points. When htt-exon1(51Q) was labeled with 1x NHSA, there was no 
significant difference in the number of oligomers compared to non-acetylated htt-
 
Figure 3. Chemical acetylation of Nt
17
 in htt-exon1 (51Q) suppresses 
aggregation. (a) Representative AFM images taken in air after 5 and 24 h of 
incubation of htt-exon1(51Q) alone or labeled with 1x, 2x, or 3x NHSA. Blue 
arrows indicate oligomers, and black arrows indicate fibrils. The number of (b) 
oligomers and (c) fibrils per unit area observed in AFM images taken of 
aggregates formed by htt-exon1(51Q) alone or labeled with 1x, 2x, or 3x NHSA 
as a function of time. The error bars represent the standard deviation. 
113 
4. Acetylation alters huntingtin aggregation and membranes 
 
exon1(51Q); however, after 8 h, there was a significant decrease in the number of fibrils 
observed compared to the control (no acetylation). Increasing the NHSA treatment to 2x 
again resulted in no significant change in the number of oligomers observed, but there 
was a clear inhibition of fibril formation as early as after 1 h of incubation. Treatment 
with 3x NHSA resulted in a significant decrease in the number of oligomers and fibrils as 
a function of time. Overall, increasing the ratio of NHSA to htt decreased the number of 
fibrils that formed in a dose dependent manner, but only at 3x NHSA were the number of 
oligomers significantly affected. 
 Next, we compared the morphology of aggregates formed under the different 
acetylating conditions (Fig. 4). As the lateral dimensions contain appreciable contribution 
from the finite size and shape of the AFM probe, comparisons between the heights of 
aggregates are presented. Fibrils of htt-exon1(51Q) with increasing acetylation tended to 
be shorter, presumably due to a decreased time for fibril expansion due to a longer lag 
phase. However, the height along the contour of these fibrils was indistinguishable (~5-
6nm, Fig. 4a), suggesting a similar fibril structure. The size distribution of oligomers 
observed varied greatly with increasing acetylation (Fig. 4b). Without any NHSA, the 
distribution of oligomer size remained relatively tight with a slight increase in the mode 
height from 5-6 nm to 6-7 nm after 24 h. The oligomer size distribution was similar up to 
5 h of incubation when 1x NHSA was added, but at 8 and 24 h a pronounced population 
of larger oligomers (~9-11 nm) began to form. This second, larger population of 
oligomers became more pronounced at earlier time points with increasing amounts of 
NHSA. With 3x NHSA, the larger population of oligomers eventually predominated the 
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size distribution. The increased size of the oligomers formed with 3x NHSA may explain 
the significant reduction in the total number of oligomers as more peptide was 




Acetylation inhibits htt/lipid interactions.  
 To determine if acetylation of Nt
17 
would alter the interaction of htt-exon1 with 
lipid membranes, a total brain lipid extract (TBLE)/polydiacetylene (PDA) vesicle lipid 
binding assay was performed (Fig. 5a). This colorimetric assay uses mixed vesicles 
comprised of phospholipids and polymerized PDA. A rapid, visible color change from 
blue to red is induced by direct interaction between peptides and the phospholipid within 




Figure 4. Acetylation of Nt
17
 in htt-exon1 (51Q) influences the size of aggregates. 
Height histograms of (a) fibrils and (b) oligomers observed in AFM images taken of 
aggregates formed by htt-exon1(51Q) alone or labeled with 1x, 2x, or 3x NHSA as a 
function of time. The number of individual aggregates measured is indicated in each 
plot. 
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membrane interactions and PDA-based vesicles have been used to study a variety of 
biological processes at membrane surfaces, including the binding of amyloid proteins 
[65, 67, 71, 72]. A quantitative value representative of the blue-to-red color transition is 
obtained by determining the % colorimetric response (%CR), defined as [67, 72] 
 
 
Figure 5. Acetylation of Nt
17
 modulates the interaction between htt-exon1(51Q) 
and lipid membranes. (a) TBLE/PDA vesicle binding assay demonstrating the impact 
of lysine acetylation by NHSA on the ability of htt-exon1 (51Q) to bind and aggregate 
on lipid membranes. (b) An AFM image of a complete, supported, TBLE bilayer on 
mica. AFM images of TBLE bilayers taken after 1 and 5 h of exposure to (c) htt-
exon1(51Q), (d) htt-exon1(51Q) + 1x NHSA, (e) htt-exon1(51Q) + 2x NHSA, (f) htt-
exon1(51Q) + 3x NHSA. Insets are zoomed in images of the indicated regions of the 
larger images. Blue arrows indicate oligomers present on the bilayer. (g) Quantification 
of the RMS roughness associated with disrupted regions of the bilayer and the percent 
area of the bilayer that has been disrupted for bilayers exposed to htt-exon1(51Q) alone 
or labeled with 1x, 2x, or 3x NHSA as a function of time. 
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%CR = [(PB0 - PBI)/PB0] × 100  (1) 
 
where PB is a red/blue ratio of absorbance (A) defined as Ablue/(Ablue + Ared). Ablue is the 
absorbance at the “blue” component in the UV-vis spectrum (≈640 nm); Ared is 
absorbance at the “red” component (≈500 nm), PB0 is the red/blue ratio of the control 
sample (before induction of color change), and PBI is the value obtained for the vesicle 
solution after addition of peptides.  
The TBLE/PDA vesicles were exposed to 20 µM htt-exon1(51Q) or htt-
exon1(51Q) that had been acetylated by NHSA (1x, 2x, or 3x), and %CR was measured 
for 16 hours (Fig. 5a). Upon exposure to htt-exon1(51Q), there was an initial steady 
increase in %CR as TBLE/PDA vesicles peptide bound and aggregated on the vesicle. 
Eventually, %CR leveled off to a quasi-steady state value. There was not a significant 
change in the %CR comparing exposures of unaltered htt-exon1(51Q) to that which had 
been exposed to 1x NHSA. After ~14 h, there was a small decrease in the %CR between 
these two samples that was significant. However, as the amount of NHSA was increased 
to 2x or 3x, there was a clear dose dependent reduction in the %CR observed, indicating 
that acetylation reduced the interaction between htt-exon1 and the lipid membrane. 
Although, there is still an appreciable interaction of htt-exon1(51Q) with the lipid 
vesicles under all conditions. 
 To further investigate the impact of acetylation on the interaction of htt-exon1 
with lipid bilayers, supported model lipid membranes through fusion of TBLE vesicles 
were prepared (Fig. 5b). Supported lipid bilayers preserve many important properties 
(i.e., lateral fluidity) of their free membrane counterparts [73, 74], and the interaction of  
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amyloid-forming proteins with these bilayers can be continuously tracked using in 
solution AFM. Smooth bilayers (as determined by AFM) were exposed to unmodified 
htt-exon1(51Q) proteins or htt-exon1(51Q) that had been acetylated with varying 
amounts of NHSA (1x, 2x, or 3x NHSA). To cleave the GST moiety, Factor Xa was 
incubated with the GST- exon 1 fusion protein on ice for 1 hour prior to exposure to the 
supported bilayer. The resulting htt-exon1 preparations predominately contain monomers 
and small oligomers [4, 63]. Upon the initial exposure of the TBLE bilayer to 20M 
freshly prepared htt-exon1(51Q), there was noticeable deposition of globular protein 
aggregates on the bilayer and regions of perturbed bilayer morphology (evidenced by an 
increase in surface roughness), consistent with previous reports (Fig. 5c) [49, 75]. The 
 
Figure 6. Exposure to htt-exon1(51Q) disrupts TBLE bilayers morphologically. A 
representative AFM image of a TBLE lipid bilayer exposed to htt-exon1(51Q) is 
presented. The colored lines in the image correspond to the profiles of the same color. 
The yellow shading on each profile represents the maximum roughness of an 
unperturbed TBLE bilayer. Arrows point to regions of the profiles that represent areas 
where partial holes or gaps have appeared in the bilayer. 
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globular aggregates were stable on the bilayer surface as they were identifiable in 
consecutive images. The extent (or area) of bilayer perturbed by htt-exon1(51Q) 
increased with time. While most of the increased roughness appeared as the accumulation 
of protein above the initial bilayer surface, height profiles across these perturbed regions 
demonstrates that gaps and cavities within the bilayer also form (Fig. 6), verifying that 
bilayer structure was disrupted. This is consistent with previous reports that demonstrated 
by calcein dye leakage assays [19] and mechanical changes in bilayers [23, 49, 75] that 
htt-exon1 can damage membranes. When TBLE bilayers were exposed to 20 M aliquots 
of htt-exon1(51Q) that had been chemically acetylated, similar morphological changes 
and globular aggregates compared with those associated with non-modified htt were 
observed within the bilayer (Fig. 5 d-f). However, the extent of bilayer perturbation 
appeared to be reduced as a function of increasing exposure to NHSA. Interestingly, fibril 
aggregates of any of the modified and nonmodified htt-exon1(51Q) proteins were not 
observed on the bilayer surface.  
In an effort to quantify the extent of interaction between the TBLE bilayer and the 
different acetylated or non-acetylated htt-exon1(51Q) proteins, analysis of the AFM 
images was performed. First, the root mean squared (RMS) roughness of the perturbed 
regions of the bilayer was measured (Fig. 5g). A freshly formed TBLE bilayer has a RMS 
surface roughness of 0.3 ±0.05 nm. To prevent error associated with the varying extent of 
perturbation of bilayer structure, RMS roughness measurements of areas that had been 
destabilized by modified or non-modified htt-exon1(51Q) were restricted only to portions 
of the images containing altered morphology. This allows for direct comparison of the 
extent of altered bilayer morphology contained within the perturbed regions. Within the 
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first hour of exposure to the different acetylated or non-acetylated htt-exon1(51Q) 
constructs, regions of the bilayer that were significantly rougher (p<0.01) than 
unperturbed bilayer were observed; however, the roughness decreased with increasing 
acetylation. The roughness associated with perturbed bilayer regions remained relatively 
constant for 4 h; however, there was a pronounced increase in roughness after 5 h of 
exposure to non-acetylated htt-exon1(51Q) or htt-exon1(51Q) with 1x NHSA.  
As the previous analysis was confined just to regions of the bilayer that exhibited 
increased roughness, we next wanted to determine the extent of bilayer perturbation as a 
function of protein acetylation. To accomplish this, the percentage of the surface that 
displayed any increased roughness was determined (Fig. 5g). While the portion of the 
bilayer perturbed by acetylated or non-acetylated htt-exon1(51Q) steadily increased with 
time, the percent of the bilayer that was morphologically altered decreased as a function 
of increased protein acetylation. The trend corresponded well with the results from the 
first 5 h of the TBLE/PDA lipid binding assays. Furthermore, it cannot be determined if 
these globular aggregates are comprised of solely peptide or if they contain lipid 
components. The mode height of the oligomers observed on the bilayer was 2-3 nm for 
all experimental conditions and all time-points; although, larger aggregates increased in 
population over 5 h. 
Due to all of the potential acetylation sites in htt-exon1 being contained within the 
Nt
17 
and the known lipid-binding properties of Nt
17
, acetylation may change the affinity 
of this domain for lipid membranes. To address this, a series of Nt
17 
peptides were made 
that contained lysine to glutamine mutations to mimic acetylation. In this series of 
peptides, there are single, double, and triple mutations. TBLE/PDA lipid binding assays 
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were performed to assess the relative affinity of these Nt
17 
peptides for lipid membranes 
(Fig. 8). By excluding the polyQ domain, the change in the %CR in the PDA assay 
associated with aggregation can be removed, and the ability of these peptides to bind can 
be directly assessed. While htt-exon1 and synthetic peptides containing the polyQ 
domains have been shown to disrupt and aggregate on lipid membranes [19, 23, 49, 75], 
pure Nt17 peptides do not permeabilize lipid membranes [27]. All of the peptides 
containing a single mutation reduced the affinity of Nt
17 
for the vesicles, with the K9Q 
and K15Q mutants having a significantly lower affinity for the membrane compared with 
the K6Q mutant. This suggests that K9 and K15 may play a greater role in the interaction 
of Nt
17 
with lipid membranes. The double and triple mutants also reduced the affinity of 
Nt
17 
for the lipid membrane; however, only to a similar extent as the K6Q mutation alone.  
 
Figure 7. Acetylation of Nt
17 
does not alter the size of oligomers of htt-exon1(51Q) 
on lipid bilayers. Height histograms of oligomers observed in AFM images taken of 
aggregates appearing on TBLE bilayers formed by htt-exon1(51Q) alone or labeled 
with 1x, 2x, or 3x NHSA as a function of time. The number of individual aggregates 
measured is indicated in each plot. 
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As the overall %CR is considerably smaller for the Nt
17
 peptides compared with htt-
exon1(51Q) (Fig. 5a), aggregation on the vesicle surface appears to be the major 
contributor to the %CR associated with exposure to the full htt-exon1.  
 
4.4 Discussion 
Although it is clear that polyQ expansion plays a key role in htt aggregation and 
toxicity, flanking sequences adjacent to the polyQ domain heavily influence aggregation, 
aggregate stability, important biochemical and functional properties of the protein, and 
ultimately htt’s role in pathogenesis. In particular, the Nt17 domain of htt influences 
localization, aggregation, and degradation of htt in a cellular context [21, 22, 43, 57, 76-
79]. Due to its ability to form an amphipathic α-helix, Nt17 functions in regulating the 
binding of htt to a variety of membranous surfaces [21]. In this study, the impact of 
acetylation of Lysine residues within the Nt
17 
domain of htt on its aggregation and 
interactions with lipid membranes was investigated. Acetylation of Nt
17 
impeded the 
formation of htt fibrils and promoted the formation of larger, globular oligomers. 
 
Figure 8. Acetylation-mimicking mutations reduce the affinity of Nt
17 
for lipid 
vesicles. TBLE/PDA vesicle binding assay performed with Nt
17 
peptides containing 
either (a) single mutation or (b) multiple mutations of lysine to glutamine to mimic 
acetylation.  
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Furthermore, acetylation lowered the affinity of Nt
17 
for lipid membranes, reducing 
membrane damage associated with exposure to htt. These include altered hydrogen 
bonding (both intrapeptide and peptide/phospholipid) and electrostatic interactions. As 
aberrant htt/lipid interactions have been implicated in a variety of toxic mechanisms, 
understanding how acetylation of Nt
17 
impact htt aggregation and its interaction with 
membranous surfaces could lead to therapeutic intervention with the potential 
implications to HD. For example, as acetylation in Nt17 is reduced in htt containing 
expanded polyQ domains in comparison with wild-type htt [80] and our data indicates 
that acetylation reduces the affinity of htt for lipid membranes, acetylating Nt17 may 
have a protective effect against htt/lipid interactions. 
Computational studies performed in the lab of Dr. Silvina Matysiak at the 
University of Maryland suggest that the reduced affinity of Nt
17 
for lipid membranes 
caused by acetylation may be due to a number of factors associated with removal of the 
positive charge on lysine. The conformational dynamics of individual Nt
17 
domains with 
differing acetylated lysines in the presence of DOPC lipid bilayers were characterized via 
a computational approach using atomistic molecular dynamics. The aim of these 
simulations was to examine early events in the surface binding of Nt
17 
domain. Along 
with the wild type Nt
17 












K9, and K15 acetylated (Nt
17
-ACK6/9/15). Simulations of each peptide interacting with 
DOPC bilayers were run for 200 ns. With unmodified Nt
17
, phenylalanine17 (F17) tended 
to insert into the membrane first, and this occurred within the first 50 ns of the 
simulation. Once F17 inserted into the membrane, hydrogen bonds with the membrane 
123 
4. Acetylation alters huntingtin aggregation and membranes 
 
were then formed by nearby K15 and serine16 (S16). For the peptides containing various 
amounts of acetylation, F17 sometimes associated with the membrane (replicate 1 for 
Nt
17
-ACK9 and replicate 1 and 2 for Nt
17
-ACK6/9/15); however, this association tended 
to be transient compared to the non-acetylated peptide. With acetylation, interaction 
between the peptides and membrane would sometimes be initiated by residues 1-3, and 
this interaction was accompanied by hydrogen bond formation between threonine3 (T3) 
and the membrane. The stability of this interaction mediated by residues 1-3 was 
variable, as sometimes the peptide would remain bound to the membrane and other times 
the peptide would detach. Due to the transient nature observed in simulations of the 
interaction of different Nt
17 
peptides and the DOPC bilayer, the energetics of these 
interactions was determined. Attractive electrostatic interactions of significant magnitude 
(-300 to -600+ kJ/mol) were often observed, but these were usually insufficient to cause 
permanent peptide association with the membrane. For permanent peptide association 
with the membrane, the magnitude of van der Waals interactions typically needed to 
exceed the magnitude of electrostatic interactions between the peptide and membrane. 
The largest contribution to van der Waals interactions between the peptide and membrane 
comes from hydrophobic residues. 
Nt
17
 directly influences the abnormal aggregation of mutant htt. Specifically, Nt
17 
has been implicated in the initial stages of htt-exon1 aggregate formation [21, 26, 30, 36, 
81]. As such, a variety of aggregation mechanisms have been proposed that are mediated 
by Nt
17
, with most supporting Nt
17 
self-association playing a key role in the formation of 
small, α-helix rich oligomers [25, 28, 82], suggesting that Nt17 promotes fibril formation 
through an oligomer mediated pathway [36, 51, 83]. With oligomers being widely 
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considered as important toxic species in HD, Nt
17
 directed oligomerization could play a 
vital role in htt-related toxicity. Indeed, self-association of Nt
17 
represents the rate-
determining step in the formation of htt-exon1 oligomers in cellular models [24, 84]. 
Here, it was demonstrated that acetylation of Nt
17 
slows htt aggregation and promotes the 
formation of larger oligomeric species. There are several plausible mechanisms that could 
explain this observation. One scenario is that acetylation promotes the formation of 
distinct htt oligomers that are off pathway to fibril formation. Alternatively, it is possible 
that acetylation stabilizes the α-helix rich structure of the oligomers, delaying the 
transition to fibrils structures and providing time for the oligomers to increase in size by 
accumulating more monomers into the aggregate [24, 26, 85-92]. Other PTMs within 
Nt
17
 have already been shown to alter htt aggregation. For example, there are three 
phosphorylatable sites in Nt
17
: T3, S13, and S16, and several studies have found that htt 
phosphorylation is associated with reduced levels of mutant htt toxicity [39, 57, 77, 78, 
93-95]. Phosphorylation mimicking mutations of T3 enhanced htt aggregation in cultured 
cells and reduced lethality and neurodegeneration in Drosophila models of HD [57]. 
Phosphorylation-mimicking mutations of S13 and S16 significantly slowed htt 
aggregation and reduced fibril stability; however, fibril structure was not significantly 
changed [26, 77]. Interestingly, phosphorylation can regulate other PTMs, such as 
acetylation, and serve as a mechanism to target proteins for degradation [96]. 
Phosphorylation of S13 has been shown to influence acetylation at K9 [78]. It was also 
demonstrate here, that chemically acetylating lysines within Nt
17 
also can slow 
aggregation into fibrils without significantly altering the fibril structure. This finding 
further support the notion that Nt
17 
plays an important role in htt aggregation and, more 
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specifically, that targeting the charged lysines within Nt
17 
may be a viable strategy for 
modulating aggregation for therapeutic purposes.  
Full-length htt is a multi-domain protein that has been implicated with numerous, 
distinct cellular functions. With regards to the potential specificity of Nt
17 
for membranes 
of different composition, many membrane-associated functions are attributable to htt, 
such as cellular adhesion [97], motility [98, 99], cholesterol and energy homeostasis 
[100], molecular scaffolding for coordination of membrane and cytoskeletal 
communication [47], and facilitating microtubule-dependent vesicle transport [48]. 
Acetylation of Nt
17
 may play a role in regulating these activities. The trafficking of htt-
exon1 between membranes associated with the ER, autophagic vacuoles, mitochondria, 
and Golgi appear to be facilitated by Nt
17
 [21, 22]. Trafficking of htt to specific sub-
cellular compartments, for example the nucleus [101, 102], can have a strong influence in 
htt-related toxicity. The Nt
17 domain can form an amphipathic α-helix (AH) [26, 35, 36], 
and number of biophysical functions are associated with AHs [103], including the ability 
to detect and bind highly curved lipid membranes [104-106]. As AHs tend to bend 
membranes weakly, their interaction with lipids can be easily regulated. With the large 
number of potential sites for post-translational modification, including acetylation, 
contained within Nt
17
, regulation of htt/lipid interactions via Nt
17 
may play a role in the 
trafficking of htt within the cellular environment. As such, the altered affinity upon 
acetylation of Nt
17
 for lipid membranes could play a role in trafficking htt within cells, 
with potential implications for both htt’s normal function and toxicity. Such a scenario 
has been demonstrated for phosphorylation of Nt
17
, which can affect the nuclear export of 
htt [21, 107]. It was also shown that acetylation of K9 plays a critical role clearance of htt 
126 
4. Acetylation alters huntingtin aggregation and membranes 
 
via the proteasome and lysosome [78]. As a result, the acetylation of Nt
17
 and its 
modulating effect on membrane affinity may play a role in a variety of normal functions 
of htt. [27, 108, 109] 
In a theoretical AH, lysines 6 and 15 would be positioned at the interface between 
the hydrophilic and hydrophobic faces. It would appear that residues located in this 
interface may play a critical role in the ability of Nt
17 
to bind membranes. Simulations of 
htt peptide fragments associated with lipid membranes indicate that K6 and K15 form 
many hydrogen bond with bilayer components [34]. All atom simulations demonstrated 
that K6 and K15 often form salt-bridges with phospholipids; however, 
K9 was predominately involved in intramolecular salt-bridges with glutamic acid 
residues within Nt
17 
[50], suggesting that perturbing these residues would likely impact 
Nt
17’s ability to bind membranes. A combination of experiments and simulations have 
indicated that the structure and orientation of Nt
17 
on membranes is mainly influenced by 
the sequestration of nonpolar residues into the hydrophobic core of a membrane; 
however, membrane composition influences the affinity of Nt
17 
for phospholipid bilayers 
via specific electrostatic interactions [34, 50]. Collectively, this suggests a potential role 
for charged lysines in Nt
17 
selectively targeting membranes of specific phospholipid 
compositions, and removing their charge via acetylation could represent a mechanism to 
regulate this specificity. In this regard, mutating charged residues in Nt
17
, including the 
lysines, to alanines alters the localization of huntingtin within cells [21]. Furthermore, 
acetylation of a lysine (K444) beyond htt-exon1 has been implicated in autophagic 
removal of mutant htt [110]. Acetylation within Nt
17
 may play a similar role by 
regulating htt’s interaction with lipid membranes [111].  
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Beyond acetylation, SUMOylation and ubiquitination can also occur at lysine 
residues within Nt
17 
and may also play a role in regulating the interaction of htt with 
membranes. SUMOylation is implicated to play a role in HD pathogenesis in both cell 
and animal models [43, 55]. Specifically, SUMOylation at K6 and K9 reduce aggregation 
in cultured cells and exacerbate toxicity in Drosophila HD models [43]. Ubiquitination 
competes for the same lysine residues as SUMOylation, but it is associated with reducing 
mutant htt toxicity by tagging it for degradation by the ubiquitin proteasome system 
(UPS) [112]. As these other PTMs, are known to be involved in htt translocation within 
cells [21, 113]. Interestingly, mutating the lysine residues in Nt
17
 to arginine reduces 
cytotoxicity of Drosophila models of HD [43]. This reduction in cytotoxicity was 
attributed to the lack of lysine residues available for SUMOylation. Acetylation of lysine 
residues is a known mechanism to regulate the SUMOylation of proteins [114]. 
Furthermore, proteomic mapping by MS verified that K9 is appreciably acetylated in 
mammalian cell lysates [44]. The role of K9 acetylation has not yet been fully evaluated; 
however, acetylation of Nt
17
 may function in to regulate SUMOylation, modulating 
toxicity associated with SUMOylation of htt [110]. 
 
4.5 Conclusion 
  As the function, localization, and aggregation of htt have all been linked to Nt
17
, 
there is a need to identify at a mechanistic level how Nt
17 
influences the formation of 
toxic aggregates and its interaction with membranes. Here, it was demonstrated that 
lysine residues play an important role in both aggregation and membrane binding, and 
this role can be affected by removal of lysine’s positive charge via acetylation. As 
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is known to occur naturally [44, 110], the biophysical impact of this 
PTM could be important in htt’s normal function, as well as have a modulating effect on 
toxicity related to mutant htt. Such knowledge is important because it could lead to better 
defined therapeutic targets (in addition to the polyQ tract) and strategies to treat HD. 
From the ongoing discussion, the importance of htt aggregation in HD has long been well 
articulated, and lipid bilayers have been shown to influence the aggregation of a variety 
of N-terminal htt fragments However, specific lipid components, such as cholesterol 
[115], sphingomyelin and gangliosides (GM1) can modulate htt aggregation on lipid 
bilayers as well. 
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5. Outlook: Other relevant post translational modifications and small molecules as 
potential modulators of huntingtin aggregation. 
 The work presented in this dissertation was aimed at elucidating interactions of htt 
with lipid membranes from both a physical and biochemical perspective. It starts with 
development and validation of supported lipid bilayers with curvature, followed by 
investigating the impact of membrane curvature on synthetic truncated htt exon 1 
mimicking peptides (Nt
17
Q35P10KK) on aggregation. This was followed by expounding 
the role of acetylation on huntingtin aggregation, both kinetically and morphologically in 
the presence of lipid membranes. The major goal of these studies was to understand 
physicochemical aspects and molecular mechanisms associated with aggregation in the 
presence of cellular and subcellular surfaces, particularly lipid membranes. The ultimate 
goal was to understand potential ways to prevent or slow down mutant huntingtin 
aggregation, and eventually leading to the development of therapies since there is no 
widely effective preventative or therapeutic treatments for HD. A broad range of research 
tools and spectrophotometric assays such ThT and PDA were employed in this study. 
However, owing to its robust ability to provide particularly useful insights related to 
neurodegenerative diseases, AFM was utilized as the primary tool in my studies. AFM 
has the unique ability to be operated in air (ex situ) and in solution (in situ), allowing 
direct probing of biological samples at solid-liquid interfaces, under nearly physiological 
conditions.  
 In future, it is important to investigate how the changing the composition of lipid 
bilayers by exogenously adding monosialotetrahexosylganglioside known as GM1, 
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influences htt binding and aggregation on lipid membranes. Several other factors that can 
potentially regulate the aggregation of htt at lipid need further investigation.  One of such 
factors is the role of several other important post translational modifications (PTMs) on 
htt aggregation on lipid bilayers. Phosphorylation and SUMOylation are some of the 
modifications that have been implicated in HD pathogenesis; however the impact of these 
modifications on htt aggregation on lipid membranes has not yet been evaluated. Finally, 
apart from PTMs, there is increasing evidence that small molecules, heat shock proteins 
(HSPs) included, could counteract common pathological mechanisms that take place in 
neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson's disease (PD) 
and HD. It is important to understand how such molecules would interfere with htt’s 
potential to form toxic oligomeric assemblies on lipid membranes. 
 
5.1 Work in progress: Lipid components modulates huntingtin aggregation on lipid 
membranes 
  The brain and membrane of neurons are enriched in different kinds of fats and/or 
lipids. GM1 which is a major component of lipid rafts is a notable example. In the brain , 
GM1 have a plethora of functions , ranging from cell signaling [1]  , to neurotransmission 
[2], suggesting that even a small reduction in GM1 levels will likely have a huge 
physiological impact on HD neurons.  In 2010, Sipione and coworkers from the 
University of Alberta, Canada, observed a reduction in the synthesis of GM1 in a variety 
of HD animal models as well as in fibroblasts in HD patients [3]. They further showed 
that neuronal cells with decreased GM1 are more susceptible to programmed cell death 
leading to neurodegeneration. What was even more intriguing about these studies is that 
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administration of GM1 by continuous infusion into YAC 128 mice, not only restores the 
GM1 levels but reverses cell apoptosis, leading to improved motor function and complete 
reversal of the impairment in YAC 128 mouse HD models [3, 4].  There could be several 
mechanisms to explain this restoration in motor function in symptomatic mice. GM1 
induces serine S13 and S16 phosphorylation, which could explain the mechanism of this 
restoration [3-5]. However, since neurons are primarily composed of lipid membranes, 
another mechanism might lie in the role of lipid membranes in HD. Considering the 
importance of these finding, together with the role of GM1 in brain neurons, and how 
lipid membranes are important in HD pathogenesis, it is therefore of paramount 
importance to understand how exogenous added GM1 affects htt aggregation on lipid 
bilayers. 
 
5.1.1 Cholesterol and GM1 alters the extent of htt-exon1 binding to lipid vesicles as 
 determined by TBLE/PDA binding assay.  
 Prior to the GM1 experiment, the impact of added cholesterol on TBLE lipids was 
evaluated as preliminary work. To verify that altering the lipid composition of TBLE 
would modulate the interaction of htt-exon1 with lipids, a TBLE/PDA vesicle lipid 
binding assay performed. As described in chapter 4, PDA is a colorimetric assay in which 
mixed vesicles composed of lipids and polymerized chromatic PDA lipids exhibit rapid 
visible color changes from blue to red prompted by interactions between biomolecular 
species and the phospholipid components within the vesicles. The colorimetric response 
can be used to quantify protein−membrane interactions. The TBLE/PDA vesicles were  
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systematically enriched with 0% (pure TBLE), 10%, 20%, or 30% cholesterol or 0% 
(pure TBLE), 5%, 10%, or 15% GM1 by mass. These vesicles were exposed to htt exon1 
protein and colorimetric response (%CR) was measured for 16 h .Characteristically, there 
is an initial steady increase in %CR as TBLE/ PDA vesicles are exposed to htt-exon1. 
The %CR tends to level off with time to a steady state. As the exogenous cholesterol or 
GM1 content was enhanced from 0% to 30% and 0% to 15% respectively, the binding of 
htt-exon1 (51Q) to the vesicles was reduced, highlight that lipid composition modulates 
htt aggregation on membranes (Fig.1 and Fig.2 respectively). The quasi-steady state 
%CR is also significantly smaller in a cholesterol or GM1 dose-dependent manner,  
 
Figure 1.  Percent colorimetric response (%CR) of TBLE/PDA vesicles containing 
various amounts of cholesterol upon exposure to htt-exon1 (51Q) plotted as a function 
of time. Error bars indicate one standard deviation (n = 3). The highlighted area 
indicates the time frame accessible with AFM experiments 
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indicating that cholesterol and GM1 reduces htt-exon1 (51Q) overall binding to and 
insertion into lipid membranes. The complete influence of cholesterol on the aggregation 
of htt on lipid membranes supported TBLE bilayers containing various amounts of 
cholesterol were further studied using AFM, and the findings have already been 
published. 
 For GM1 studies, as in cholesterol, further studies to explore the impact of GM1 
on the aggregation of htt on supported TBLE bilayers containing various amounts of 
GM1 were conducted. Lipid bilayers were exposed to htt-exon1 and continuously imaged  
 
Figure 2.  Percent colorimetric response (%CR) of TBLE/PDA vesicles containing 
various amounts of GM1 upon exposure to htt-exon1(51Q) plotted as a function of 
time. Error bars indicate one standard deviation (n = 3).  
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using in situ AFM, allowing for the direct tracking of protein aggregation on the bilayer. 
Bilayers comprised of pure TBLE, TBLE + 5% GM1, and TBLE + 10% GM1 were used.  
As shown in Fig.3, as GM1 is enriched, the bilayers slow down htt aggregation, 
suggesting that GM1 could one potential way to control aggregation of htt on lipid 
bilayers. This supports other studies, which reported that restoring GM1 levels in HD 




Figure 3. GM1 alters the interaction of htt with supported lipid bilayers. Increasing 
the GM1 content of lipid bilayers reduces htt aggregation.  
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5.2 Future studies:  
5.2.1 Post translational modifications (PTMs) on huntingtin aggregation. 
 There are other important PTMs on Nt
17 
that could be crucial modulators of htt 
aggregation and toxicity. The commonly studied ones are SUMOylation and 
phosphorylation [6-8]. SUMOylation is the enzymatic covalent attachment of SUMO 
(small ubiquitin-like modifier proteins) to the lysine residues of a target protein. SUMO 
are 11kDa proteins that are highly conserved in a variety of species and can be 
enzymatically reversibly attached to lysine residue of htt [9, 10]. The SUMO conjugation 
pathway is a three step process involving the use of the heterodimer E1 activating 
enzyme (Ubc2/ Aos1) , an E2 conjugating enzyme (Ubc9) and the E3 ligating enzymes 
[11, 12]. The Nt
17
 domain of htt exon 1 contains three potential lysine SUMOylation 
sites, (K6, K9 and K15), and this domain also functions in lipid binding. The 
SUMOylation of lysines 6 and 9 (K6, K9) in the drosophila HD model expressing htt was 
found to enhance neurodegeneration [13] ,while in cultured striatal neurons, 
SUMOylation stabilizes htt exon 1 and decreases its aggregation. It is evident that 
SUMOylation has been linked to HD pathogenesis [13-16], but the mechanistic details is 
often still poorly understood [13, 15] , and the question still remains, what is the 
mechanism of pathology?  Htt is found in association with brain lipids [17, 18] and 
membranes in cells [19], and PTMs are thought to regulate the lipid/htt interaction [20]. It 
has also been reported that various cellular components as well as lipids modulates htt 
aggregation and toxicity [21-23]. The studying of SUMOylation on htt’s interaction with 
lipid membranes has not yet been explored. SUMOylation has been involved in the 
trafficking of htt, and this involves the interaction of htt with lipid vesicles. In subsequent 
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projects, it therefore important to investigate the impact of SUMOylation on htt 
aggregation at lipid interfaces in order to get mechanistic details of how SUMOylation 
influences htt aggregation and how SUMOylated htt interacts with lipid membranes with 
potential implications to HD. 
 Phosphorylation is another extensively studied PTM in which a phosphate group 
or a phosphate mimics is added to the threonine or serine residues of a protein. In context 
of htt exon 1, the Nt
17 
has three phosphorylation sites, threonine 3 (T3) and serines 13 and 
16 (S13 and S16). It was shown that phosphomimetic mutation of S13 and S16 by 
aspartic acid substitution, resulted in decreased toxicity of mutant htt in different animal 
models of HD possibly by changing protein conformation and function [5, 24, 25]. Since 
surfaces, particularly lipid membranes, play important roles in neurodegenerative 
diseases, it is imperative to understand how htt phosphorylation modulates the protein 
aggregation at lipid interfaces. 
 
5.2.2 Targeting huntingtin Nt
17 
with small molecules  
 The Nt
17 
domain inn htt exon 1, both in free solution and in the presence of lipids, 
has been found to influence the formation of various aggregate species including the 
small, highly diffuse, and more toxic oligomers [26, 27]. One of the several ways to slow 
down protein aggregation or change aggregation pathway is by blocking Nt
17
 or making 
itin unavailable for self-association [26, 28-30]. From previous studies, polyproline 
(polyP) PPII type helix can have a regulatory effect on aggregation Nt
17 
[31]. 
Collaboratively I carried out preliminary studies (unpublished) on how polyP peptides 
interact with   Nt
17
 of htt exon 1. Htt exon 1 was co-incubated with polpP peptides at  
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C and incubated for 24hours to allow aggregate formation. As shown Fig.4, htt exon 
1 forms well defined fibrils in a time –dependent manner. After incubation with Nt17 and 
polyP, the fibril formation is greatly reduced. This is in agreement with previous 
  
Figure 4. Representative AFM images: Images of htt exon 1 at different type points 
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observations in which oligomers are observed when htt is incubated with polyP, 
suggesting that polyP peptide has inhibitory effect on amyloid formation [5]. This could 
be due to the polyP peptide interacting with the polyQ domain, stabilizing it and prevents 
the transition to β-sheet structure. 
 It has further been reported that under bulk conditions, several amyloid inhibitors 
prevent the formation of aggregate forming species in neurodegenerative [32]. It has also 
become evident that amyloidal species such as oligomers and fibrils exert their toxic 
effects at cellular membranes than in bulk solution.  Studying how small molecules such 
heat shock proteins (Hsc70), EGCG, or curcumin interact with htt at the phospholipid 
interface could provide critical information on mechanisms by which such molecules 
inhibit amyloid formation associated with neurodegenerative. In a separate study, fatty 
acid metabolism and its compartmentalization appeared disordered in individuals with 
HD [33]. Fatty acids composition has also been implicated in the fluidity of lipid 
membranes and HD patients have altered membrane fluidity. The precise mechanism on 
how omega-3-fatty acids contribute to HD pathology especially on sub-cellular surfaces, 
is not well understood, and needs to be further attention.  
 
5.3. Concluding remarks and Perspectives 
 Huntington’s disease is a fatal, neurodegenerative disorder caused by an 
expansion of the polyQ tract in first exon 1 of htt. It is slightly more than two decades 
after the discovery of the IT15 gene, and several strides in HD have been yielding very 
promising results but no effective treatment has been identified to date, and much more 
remains to be understood about HD pathogenesis. The results presented in this 
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dissertation provide some invaluable insights into some of the physicochemical properties 
of htt aggregation both in bulk solution and at lipid interface with potential implication 
for HD. 
 In the first and second part of my PhD work, supported lipid bilayers comprised 
with curved and flat regions to demonstrate that membrane curvature plays an important 
role in htt aggregation were developed and validated. AFM in solution is a widely 
valuable technique to study morphological and mechanical properties of supported lipid 
bilayers, but one of the limitations associated with comparing these results to 
physiologically relevant membranes is the lack of membrane curvature associated with 
such systems. When exposed this system of bilayer to an N-terminal htt fragment, the 
peptide preferentially accumulated on curved regions of the bilayer. This accumulation 
and disruption may represent a mechanistic detail of disruption of the normal lipid 
associated functions of htt may play a role in toxicity associated with expanded polyQ 
domains. Apart from physical properties of membranes, several chemical properties can 
potentially play a role in regulating the interaction of htt exon1 fragments facilitated by 
Nt
17
 with lipid membranes. This took me to my third project on how acetylation 
modulates the binding of htt to lipid membranes. It was demonstrated that lysine residues 
play an important role in both aggregation and membrane binding, and this role can be 
affected by removal of lysine’s positive charge via acetylation. The biophysical impact of 
this PTM could be important in htt’s normal function, as well as have a modulating effect 
on toxicity related to mutant htt, and could lead to better defined therapeutic targets. 
Finally, adding small amounts of exogenous Cholesterol and GM1 to TBLE bilayers was 
found to be another way to slows down htt aggregation.  
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 Overall, the findings presented here further underpinned the groundwork of HD 
research, with the eventual goal of providing insights for the development of therapeutic 
targets and treatment of this devastating disease. Considering the emerging impact of 
small molecules in neurodegenerative diseases, further studies will be required to 
understand the mechanistic of roles of these molecules (EGCG, curcumin, Hsc70) on htt 
aggregation at lipid interfaces other than bulky solution as this could have an enormous 
importance in HD therapeutic development. 
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